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8Chapter 1:  
Summary
Over the past decades cervical cancer has become significantly less common in 
those countries where screening has been introduced, nevertheless it is still the 
second most common cancer in developing countries. Worldwide it is responsible 
for about 266,000 deaths each year. The International Federation of Gynecology 
and Obstetrics (FIGO)-staging system is the principal instrument in the staging 
of cervical cancer. Although it is used for almost a century no data on the accu-
racy of this staging system are available. Therefore, in order to investigate its 
reliability and reproducibility, we performed a prospective study to evaluate the 
interobserver agreement of the examination under anesthesia on which FIGO 
staging mainly is based. In addition we evaluated possible confounding factors 
of FIGO staging. The interobserver agreement among experienced investigators 
is only moderate. This could indicate possible limitations for sharing and com-
paring results based on this staging system. Our data demonstrated a significant 
better agreement between experienced investigators compared to the agree-
ment between an experienced and an inexperienced investigator. This implies 
that clinical gynecological examination is a skill that can be improved by training. 
A close look to the disagreement patterns on FIGO stage showed that in case of 
discrepancy the inexperienced investigator tended to underestimate the disease 
stage (by rating the FIGO stage lower than the rating of the experienced exam-
iner) and consequently recommended surgery in patients that were considered 
inoperable by the experienced examiner. This could result in a suboptimal treat-
ment with an increased risk of morbidity and higher medical costs. Multivariate 
analysis could not demonstrate any patient or tumor related characteristics with a 
significant impact on the interobserver agreement of FIGO staging. In conclusion 
we could say that our data, demonstrating the importance of experience of the 
investigators in staging of cervical malignancies, are strong additional arguments 
for centralization of care in cervical cancer patients. 
9Since the addition of chemotherapy to radiotherapy, the survival rates of 
locally advanced cervical cancer (LACC) have improved but are still disappoint-
ing. Therefore, the idea of surgery after chemoradiation in case of LACC or bulky 
disease was adopted. The rationale for this idea is to obtain a better local control 
that might translate into a better overall survival. One of the concerns regarding 
surgery following chemoradiotherapy is surgery-related morbidity. The imple-
mentation of advanced radiotherapy techniques with a higher radiation dose on 
the target volume and less damage to the organs at risk creates opportunities to 
safely perform radical hysterectomy and a tailored lymphadenectomy. Our data 
demonstrated complication rates of type II hysterectomy after intensity modu-
lated arc therapy (IMAT) with concomitant chemotherapy to be acceptable and 
comparable to complication rates of radical surgery for low-stage cervical cancer.
In order to reduce the overall toxicity of the treatment in patients with LACC 
it would be opportune to be able to select patients with residual disease after 
the initial chemo radiation therapy that would benefit adjuvant treatment. Conse-
quently this would mean that one would be able to avoid additional brachytherapy 
and/or surgery in patients without residual disease. This could minimalize the 
treatment toxicity without deteriorating the prognosis. We evaluated the value of 
cervical biopsy in predicting residual disease after initial chemo radiation therapy. 
Only in half of the patients with residual disease (sensitivity of 50%) cervical 
biopsies could prove malignancy. This indicates it is not reliable for evaluating 
treatment response. We therefore can not recommend routine application of this 
technique for selecting LACC patients for additional treatment.
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Chapter 1:  
Samenvatting
De voorbije decennia is in landen waar een screening naar cervixafwijkingen werd 
geïntroduceerd de incidentie van baarmoederhalskanker aanzienlijk gedaald. In 
ontwikkelingslanden daarentegen is cervixcarcinoom echter nog steeds de tweede 
meest voorkomende kanker bij vrouwen. Wereldwijd is baarmoederhalskanker 
jaarlijks verantwoordelijk voor ongeveer 266,000 sterftegevallen. De stagering van 
het cervixcarcinoom gebeurt volgens de richtlijnen van de Internationale Federatie 
voor Gynaecologie en Verloskunde (FIGO). Hoewel deze reeds bijna een eeuw 
gebruikt worden, zijn er geen gegevens bekend over de nauwkeurigheid ervan. Wij 
onderzochten daarom de betrouwbaarheid en reproduceerbaarheid van de FIGO 
classificatie aan de hand van de hoeveelheid “eensgezindheid” tussen de verschil-
lende onderzoekers bij het bepalen van het FIGO stadium. Bij ervaren onderzoe-
kers was de eensgezindheid betreffende het FIGO stadium matig. Dit kan duiden 
op eventuele beperkingen van de FIGO classificatie in de bruikbaarheid bij het 
uitwisselen en vergelijken van resultaten. Uit onze gegevens blijkt daarenboven dat 
er een significant betere eensgezindheid is betreffende het FIGO stadium tussen 
ervaren onderzoekers in vergelijking met de eensgezindheid tussen een ervaren 
en een onervaren onderzoeker. Dit impliceert dat het klinisch gynaecologische 
onderzoek een vaardigheid is die kan aangeleerd worden. In het geval van onenig-
heid tussen een ervaren en een onervaren onderzoeker bleek dat de onervaren 
onderzoeker systematisch de uitgebreidheid van de ziekte onderschatte. Bijgevolg 
adviseerde deze dan ook vaker heelkunde in gevallen waar de ervaren onder-
zoeker voor chemo radiotherapie opteerde. Dit kan leiden tot een suboptimale 
behandeling met een verhoogd risico op morbiditeit en hogere medische kosten. 
Er konden via multivariate analyse geen tumor of patiënt gerelateerde kenmerken 
weerhouden worden die de klinische stadiëring van baarmoederhalskanker zouden 
beïnvloeden. Samenvattend kunnen we stellen dat deze gegevens, die het belang 
van de ervaring bij stagering van cervixcarcinoom aantonen, sterke aanvullende 
argumenten zijn voor centralisatie van zorg bij deze patiënten. 
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De toevoeging van chemotherapie aan radiotherapie zorgde voor een aan-
zienlijke verbetering in overlevingskansen van patiënten met een lokaal gevor-
derd cervixcarcinoom. Toch blijven de overlevingskansen teleurstellend. Daarom 
opperden een aantal onderzoeksgroepen het idee om na de behandeling met 
chemo radiotherapie een aanvullende hysterectomie te verrichten. De ratio-
nale hierachter is dat door het verwijderen van de initiële tumorlokalisatie de 
potentieel radiotherapie resistente tumorcellen verwijderd worden waardoor een 
betere lokale controle kan bekomen worden die dan zou kunnen resulteren in 
betere overlevingskansen. De vrees voor bijkomende toxiciteit ten gevolge van 
de heelkunde is de voornaamste reden voor de terughoudendheid ten aanzien 
van deze behandeling. De introductie van geavanceerde radiotherapie, met een 
hogere stralingsdosis op het doelvolume en minder schade aan de omliggende 
organen, opent nieuwe perspectieven voor aanvullende heelkunde. Onze data 
toonden aan dat het aantal complicaties ten gevolge van type II hysterectomie na 
een initiële behandeling met intensiteit gemoduleerde boog therapie (IMAT) met 
concomitante chemotherapie aanvaardbaar is en zelfs vergelijkbaar is met deze 
van radicale chirurgie bij een primair laag stadium cervixcarcinoom. 
Teneinde de totale toxiciteit van de behandeling bij patiënten met lokaal 
geavanceerde ziekte te reduceren zou het opportuun zijn indien we de aanwe-
zigheid van residuele ziekte na de initiële behandeling correct konden inschatten. 
Patiënten met residuele ziekte zouden dan een aanvullende behandeling kunnen 
krijgen middels heelkunde of brachytherapy. De patiënten met een complete res-
pons op de initiële behandeling zouden dan gespaard kunnen worden van een 
nabehandeling. In dit kader onderzochten we de mogelijkheid om door middel 
van een cervix biopsie een uitspraak te doen over de aanwezigheid van residuele 
ziekte na de initiële behandeling. De betrouwbaarheid hiervan bleek onvoldoende 
(sensitiviteit van 50) voor het selecteren van patiënten.
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Chapter 2:  
Introduction
2.1 Background information on cervical cancer
Cancer of the cervix is the fourth most common cancer in women worldwide. In 
2012, about 528,000 new cases and 266,000 deaths were estimated (7.5% of 
all female cancer deaths). A large majority of the global burden (around 85%) 
occurs in the less developed regions, where it accounts for almost 12% of all 
female cancers. High-risk regions include Melanesia and Southern, Eastern and 
Middle Africa (in the last two it remains the most common cancer). Rates are 
lowest in Australia/New Zealand and Western Asia. Worldwide, the mortality rate 
from cervical cancer is around 50%1 Global incidence and mortality rates depend 
upon the presence of screening programs for cervical pre-cancerous lesions2,3 
and of human papillomavirus vaccination4, which are most likely to be available 
in developed countries. Due to these interventions, a 75% decrease in incidence 
and mortality of cervical cancer has been noticed in industrialised countries over 
the past 50 years. Hence it is not surprising that almost nine out of ten (87%) cer-
vical cancer deaths nowadays occur in the less developed regions.1
 
 INCIDENCE DEATHS
 NUMBER % RANKING NUMBER % RANKING
World 527624 8,8 4 265653 7,5 4
Europe 33679 2,8 8 13117 2,3 12
Belgium 639 2,3 9 219 2,3 15
TABLE 2.1: cervical cancer Incidence and Deaths (based on GLOBOCAN 2012 reports). 1
Human papillomavirus (HPV) is the key factor behind the development of cer-
vical neoplasia and cervical cancers and a persistent infection by an oncogenic 
HPV type is a condition sine qua non5,6,7,8. The presence of HPV in virtually all 
cervical cancers (worldwide HPV prevalence in cervical carcinomas is 99.7%) 
implies the highest worldwide attributable fraction for a specific cause of cancer. 
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Target zone for infection is the epithelial transformation zone. Genital HPV types 
(over 40 subtypes) are subdivided into groups based on their oncogenic potential. 
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 are consid-
ered to be of high oncogenic risk (High Risk HPV)9. The first two, HPV types 16 
and 18 account for approximately 50% and 20% of all cervical cancers10,11. The 
two available vaccines against HPV 16 and 18 (®Gardasil (Merck) and ®Cervarix 
(GlaxoSmithKline)) were evaluated in large randomized controlled trials and both 
were found nearly 100% effective in preventing new infections in previously unaf-
fected women12,13,14 and thereby have the potential to reduce the risk on cervical 
cancer by more than 70%4. However, affordable pricing is the most critical factor 
to facilitate the introduction of HPV vaccines in low- and medium-resource coun-
tries in the short term15. In addition in these regions the vast majority of women 
infected with human immunodeficiency virus (HIV) will be co-infected with human 
papillomavirus (HPV). The interaction between the two sexually transmitted infec-
tions appears to be related to the alteration in cell-mediated immunity in HIV 
infected persons, increased susceptibility, and possibly reactivation of a latent 
HPV infection.16
FIGURE 2.1: Estimated Cervical Cancer incidence worldwide in 2012 (GLOBOCAN 2012). 1
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Over three-quarters of cervical cancer cases occur in 25-64 year olds. There 
are two peaks in the age-specific incidence rates: the first in women aged 45-49 
and the second in women aged 75-79. The first peak is related to many women 
becoming sexually active in their late teens/early 20s, giving rise to an increase 
in HPV infections. The second peak is due to increasing cancer incidence with 
age and increased altered relationships during midlife.
FIGURE 2.2: Age distribution of absolute numbers (a) and crude incidence (b) of cervical cancer  
  in Belgium (based on data 2011).17
15
The most common histologic types of cervical cancer are squamous cell carci-
noma and adenocarcinoma, accounting for approximately 70% and 25% each. The 
other 3 to 5% consist of neuroendocrine (predominantly small cell carcinoma) and 
other rare cell types (the WHO histological classification is shown in TABLE 2.2). 
WHO histological classification of tumours of the uterine cervix
Epithelial tumours
Squamous tumours and precursors
   Squamous cell carcinoma, not otherwise specified
   Early invasive (microinvasive) squamous cell carcinoma
   Squamous intraepithelial neoplasia
   Benign squamous cell lesions
 Glandular tumours and precursors
   Adenocarcinoma
Mucinous adenocarcinoma
Endometrioid adenocarcinoma
Clear cell adenocarcinoma
Serous adenocarcinoma
Mesonephric adenocarcinoma
   Adenosquamous carcinoma
   Neuroendocrine tumours
   Undifferentiated carcinoma
Mesenchymal tumours and tumour-like conditions
   Leiomyosarcoma
   Endometrioid stromal sarcoma, low grade
   Undifferentiated endocervical sarcoma
Mixed epithelial and mesenchymal tumours
   Carcinosarcoma (malignant müllerian mixed tumour)
   Adenosarcoma
Melanocytic tumours
   Malignant melanoma
   Blue naevus
Miscellaneous tumours
Tumours of germ cell type
Lymphoid and haematopoetic
   Malignant lymphoma (specify type)
   Leukaemia (specify type)
Secondary tumours
TABLE 2.2:  WHO Classification of Histological types cervical cancer (short version).23  
 For the complete version see http://screening.iarc.fr/atlasclassifwho.php?lang=1 
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The incidence of invasive cervical adenocarcinoma has increased dramatically 
over the past few decades18,19,20. Several causative factors have been proposed 
explaining this trend: 1) increasing prevalence of specific HPV variants that are 
associated more with adenocarcinoma6, 2) exposure to exogenous (e.g. hormonal 
contraception, hormonal substitution therapy) 21,22 and endogenous (e.g. obesity) 
oestrogens. 
 
2.2 Staging of cervical cancer
Cancer staging is one of the fundamental activities in oncology and is of pivotal 
importance to modern management of cancer patients. The purpose of cancer 
staging is to reach an uniform/unified terminology that is able to provide appro-
priate prognosis to the patients, to enhance the exchange of information among 
health professionals, to compare outcome between centres and to create a com-
mon language to facilitate making diagnoses and treatment plan. To achieve this 
objective, staging systems should be evidence-based, reproducible and user-
friendly.
Over the years, most staging systems for gynaecological malignancies have 
shifted from a clinical to a surgical-pathological basis. In contrast to other gyne-
cological cancers, cervical cancer staging remains mainly a clinical staging. This 
is because the majority of cervical cancers take place in low resource countries 
where additional staging tools are not generally available. 
Cervical cancer staging is the oldest staging system in the literature, dating 
back to 1928 when, for the first time, physicians grouped cancer of the cervix uteri 
into different stages according to the extent of tumor growth. Since then, the Inter-
national Federation of Gynecology and Obstetrics (FIGO) has developed a widely 
accepted staging system for cervical cancer24. A latest update of the FIGO staging 
system was published in 2009 by Pecorelli et al.25. The FIGO stage is assigned 
at the time of diagnose. Stages are defined by tumor size and extension of dis-
ease beyond the cervix to adjacent tissues including vagina, parametria, sacro- 
uterine ligaments, pelvic sidewalls, bladder, or rectum. In this staging system, 
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Primary tumor (T)
TNM FIGO Surgical-Pathologic Findings
TX  Primary tumor can not be assessed
T0  No evidence of primary tumor
Tis  Carcinoma in situ (pre-invasive carcinoma)
T1 I Cervical carcinoma confined to the cervix (disregard extension to the corpus)
T1a IA
Invasive carcinoma diagnosed only by microscopy; stromal invasion with a 
maximum depth of 5.0 mm measured from the base of the epithelium and 
a horizontal spread of 7.0 mm or less; vascular space involvement, venous 
or lymphatic, does not affect classification
T1a1 IA1 Measured stromal invasion ≤ 3.0 mm in depth and ≤ 7.0 mm in horizontal 
spread
T1a2 IA2 Measured stromal invasion > 3.0 mm and ≤ 5.0 mm with a horizontal spread 
≤ 7.0 mm
T1b IB Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2
T1b1 IB1 Clinically visible lesion ≤ 4.0 cm in greatest dimension
T1b2 IB2 Clinically visible lesion > 4.0 cm in greatest dimension
T2 II Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina
T2a IIA Tumor without parametrial invasion
T2a1 IIA1 Clinically visible lesion ≤ 4.0 cm in greatest dimension
T2a2 IIA2 Clinically visible lesion > 4.0 cm in greatest dimension
T2b IIB Tumor with parametrial invasion
T3 III Tumor extends to pelvic wall and/or involves lower third of vagina and/or 
causes hydronephrosis or non-functional kidney
T3a IIIA Tumor involves lower third of vagina, no extension to pelvic wall
T3b IIIB Tumor extends to pelvic wall and/or causes hydronephrosis or  
non-functional kidney
T4 IV Tumor invades mucosa of bladder or rectum and/or extends beyond  true pelvis 
T4a IVA Tumor invades mucosa of bladder or rectum
T4b IVB Tumor extends beyond true pelvis
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis (including peritoneal spread; involvement of supra-clavicular, 
mediastinal, or para-aortic lymph nodes; and lung, liver, or bone)
TABLE 2.3: TNM and FIGO classification of cervical cancer.
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cervical cancer is staged predominantly by physical pelvic examination. This 
pelvic examination is ideally performed under anaesthesia (EUA), which allows 
optimal clinical evaluation. Some additional examinations are allowed: hysteros-
copy, cystoscopy, proctoscopy, abdominal ultrasound, intravenous pyelogram, 
and imaging with a plain radiograph of the lungs and skeleton. These additional 
tests are not mandatory for every patient but when performed results can help in 
staging. Findings of optional examinations, e.g. laparoscopy, ultrasound, Com-
puter Tomography (CT) scan, Magnetic Resonance Imaging (MRI), and Positron 
Emission Tomography (PET) scan are of value for planning therapy but, because 
these are not generally available and the interpretation of results is variable, the 
findings of such studies should not be the basis for changing the FIGO staging.
The limitations of FIGO staging are well appreciated. The most important 
being lymph node status, which, although an important prognostic parameter, is 
not incorporated.26 
The clinical assessment of parametrial and sidewall invasion can be difficult. 
These limitations can lead to under- or overstaging of some patients. Clinical 
staging appears to perform best for early or late stage disease, but less well for 
stages that depend largely upon assessment of tumor size or local spread. For 
these reasons, additional testing modalities (MRI, CT, PET-CT) are used (when 
available) to evaluate cervical cancer. The results of these tests are used for plan-
ning treatment.27, 28
Although FIGO staging is often reported in treatment planning, the Inter-
national Federation of Gynecology and Obstetrics has always maintained that 
staging is intended for comparison purposes only and not specifically as guide 
for therapy.
The American Joint Committee on Cancer (AJCC) and the Union for Interna-
tional Cancer Control (UICC) created a TNM classification system that is parallel 
to the FIGO system29. If a case was treated surgically, the pathologic TNM nomen-
clature (pTNM) is appropriate to report the pathological extent of the disease and 
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it can help in decision-making on adjuvant treatment and in reporting prognosis to 
patients. It should, however, not be used to alter the initial (clinical) FIGO staging.
FIGO Stage Number Average age
I 257 48,7
II 53 57,7
III 96 57,4
IV 63 65,4
Unknown stage 154 60,5
 Total number cervical cancers 623 55,4
 Carcinoma in situ of cervix uteri 2926 36,6
TABLE 2.4: Number of new diagnoses of cervical cancer and average age per stadium in Belgium 30.
Although used for almost a century as the principal instrument in staging 
(and indirect in decision making) of cervical cancer no data on the accu-
racy of FIGO staging are available. Therefore, in order to investigate its 
reliability and reproducibility, we performed a prospective study (see chap-
ter 4) to investigate the interobserver agreement of the examination under 
anesthesia (EUA) on which FIGO staging (mainly) is based. In addition we 
evaluated it on possible confounding factors.
2.3 Prognosis of cervical cancer
Worldwide the five-year overall survival (OS) rate is estimated to be 65%, in 
Belgium it is 69,8%. These OS rates depend on the extent of the disease: in 
small tumors, limited to the cervix, the five-year survival rate is 93%. As shown 
in TABLE 2.5, the 5y-OS decreases dramatically in case of disease extension 
beyond the pelvis or distant metastases.31 In Belgium, as in most industrialized 
countries, the disease is diagnosed in the majority of cases at an early stage. This 
explains the relative high 5y-OS rate. Research by the Organization for Economic 
Cooperation and Development shows that this relative 5y-OS in Belgium is similar 
to that in other European countries. Based on data for the period 2002-2004 
the survival in Norway is significantly better than in Belgium, while that of the 
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United Kingdom and Ireland is worse32. The EUROCARE study, which is based 
on patients who were diagnosed between 1995 and 1999 and were followed until 
December 2003, reports similar findings33.
FIGO Stage 5-Year Observed Survival Rate
IA 93%
IB 80%
IIA 63%
IIB 58%
IIIA 35%
IIIB 32%
IVA 16%
IVB 15%
TABLE 2.5:  The 5-year observed survival rates based on the 7th edition of the AJCC staging man-
ual from data collected by the National Cancer Data Base, based on people diagnosed 
between 2000 and 2002.
FIGURE 2.3: Five-year survival for in situ and invasive cervical cancer in Belgium (2004-2008),  
 per stage 30.
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The stage at diagnosis and survival after diagnosis are strongly influenced by 
the socio-economic status. Women who live in areas with more poverty are 20% 
more likely to be diagnosed with late-stage cervical cancer than those in a richer 
area. Regardless of the stage at which they are diagnosed, women who live in 
poorer areas have a lower 5y-OS (about 7%).34
 
2.4 Treatment of primary cervical cancer
Cervical cancer treatment depends on disease stage and tumor size. In non-bulky 
tumors (<4cm) confined to the cervix or with minimal extension to the proximal 
vagina (early stage cervical cancer), (radical) surgery is usually primary opted 
for. Radiotherapy in combination with chemotherapy (CRT) is the treatment of 
choice in all other, non-metastasized patients (locally advanced cervical cancer). 
Palliative chemotherapy and palliative radiation therapy are usually the choice in 
case of metastatic setting (stage IVB).35, 36
2.4.1 Treatment of early stage cervical cancer
The extent of the hysterectomy depends on the size and characteristics 
of the disease. Tumors of limited size without aggressive characteristics 
(FIGO IA1or IA2 without lymph vascular invasion (LVI)) can be treated by 
conisation in order to conserve fertility or by simple hysterectomy in case 
of completed family planning. Tumors with a diameter larger than 7mm or 
with an infiltration depth of more than 5 mm confined to the cervix or with 
minimal extension to the proximal vagina are mainly treated with radical 
(Wertheim) surgery when there is no desire to conceive. The first large 
series (500 patients) of radical hysterectomy in the treatment of cervical 
cancer was reported by Ernst Wertheim in 1912.37 Since then there have 
been several variations in the surgical technique of hysterectomy. The radical 
hysterectomy today is commonly categorized by amount of parametria 
resected. These variations are, based on their extent, traditionally divided 
in five classes as described by Piver et al. in 1974 (called Piver classes).38 
The first three classes are used in the primary treatment of cervical carcinoma. 
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Piver class I hysterectomy is a slight extension of a simple hysterectomy 
with removal of a small part of the parametrium. The Piver class II hys-
terectomy removes a more generous part of the vaginal cuff, ligates the 
uterine artery on the medial side of the ureter (but does not dissect it from 
the vesico-uterine ligament), and removes the inner one third of the car-
dial ligament. The Piver class III operation with removal of all of the para-
metrium and para-vaginal tissue in addition to the pelvic lymph nodes is 
considered the classic Wertheim-Meigs procedure. Landoni et al.39 demon-
strated that Class II and class III radical hysterectomies are equally effec-
tive in surgical treatment of cervical carcinoma, but class II is associated 
with a lesser degree of late complications. The last two classes (Piver IV 
and V) are more extensive procedures, generally reserved for patients with 
recurrent disease.38
Surgical advances in the last decades have put attention on quality of 
life (QOL) of patients. This has led to a growing trend for nerve sparing 
surgery in order to decrease urologic and gastrointestinal morbidities.40 
In addition, fertility conserving surgery with trachelectomy seems to be safe 
in certain subsets of patients.41
FIGURE 2.4: Piver class II and III radical hysterectomy – image from the right side wall  
(Piver MS, 1974) . 38
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The description and specification of anatomic landmarks in Piver’s clas-
sification does not allow for precise reproducibility. As a consequence, the 
extent of parametrial resection may vary substantially across institutions 
and surgeons, even if the same terminology is used. Therefore Querleu 
and Morrow42 published a classification system proposal (slightly adapted 
in 2011 by Cibula43) describing four types of radical hysterectomy (A-D), 
which can be precisely defined on a three-dimensional anatomical tem-
plate and includes nerve-sparing procedures. This new system is more and 
more promoted to become the new standard. 
Recent data indicate non-radical surgery (simple hysterectomy + pelvic 
lymphadenectomy) for the treatment of early stage cervical cancer (max 
IB1 (< 2cm)) seems to be a safe and reasonable option in well-selected 
patients who have favorable prognostic factors. This approach reduces 
operative morbidity44 (Bouchard-Fortier GO 2014). We are waiting for the 
results of three large prospective trials (SHAPE45, GOG-027846; ConCerv47) 
on this topic. 
New Classification System Corresponding Historical Types
A Extrafascial hysterectomy
B Piver Type II radical hysterectomy
C1 Nerve-sparing radical hysterectomy
C2 Piver Type III radical hysterectomy
D Laterally extended parametrectomy
TABLE 2.6:  Proposed classification system and corresponding historical types of radical 
hysterectomy.48
2.4.2 Treatment of bulky and locally advanced cervical cancer
It was the discovery of radium more than a century ago that revolution-
ized the management of cervical cancer. Before the 20th century, inoper-
able equated to untreatable. By the early 1920s, the combination of both 
external beam deep x-ray treatment and brachytherapy had become the 
standard. Over the next 80 years or so, this basic treatment paradigm was 
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never improved. It was not until 1999 that the outcome of cervix cancer 
radiotherapy chanced significantly. Since the meta-analysis of Green et 
al in The Lancet in 200149 the combination of radiotherapy (RT, unless 
mentioned otherwise this equals always external beam radiotherapy) and 
chemotherapy followed by brachytherapy has been recommended as 
standard treatment for bulky (>4 cm) IB and locally advanced cervical can-
cer (LACC) up to stage IVA. The additional effect of chemotherapy, when 
added to radiotherapy, was evaluated again in 2005 by Green et al.50 in a 
Cochrane review of 24 trials concerning 4921 patients. The review strongly 
suggests that chemoradiation (CRT) improves OS and progression free 
survival (PFS), whether or not platinum was used, with absolute benefits 
of 10% and 13% respectively. Chemoradiation also showed significant 
benefit for local recurrence and a suggestion of a benefit for distant recur-
rence. This puts forward the hypothesis that concomitant chemotherapy 
may afford radio-sensitisation and systemic cytotoxic effects. Acute hae-
matological and gastrointestinal toxicity was significantly greater in the 
concomitant CRT group. 
Conventional pelvic RT uses bony landmarks as seen on planar X-rays 
to define the target volume. Treatment is delivered either with anterior and 
posterior opposed fields or with a 4-field box technique, which reduces the 
volume of the small bowel in the treated volume. Conventional RT, while 
highly effective, delivers ionizing radiation not only to the target tumor vol-
ume but also to significant areas of adjacent normal tissue, accounting 
for many of the observed acute (diarrhea, cystitis) and late (small bowel 
obstruction from luminal narrowing and fibrosis, chronic proctitis, sigmoid 
strictures, ureteral stricture, chronic hemorrhagic cystitis) tissue toxicities.51, 
52
 These potential complications limit the total radiation dose that can be 
safely delivered. 
In an attempt to increase the ratio of prescribed radiation dose given 
to the tumor (Planning Target Volume (PTV)) as opposed to the Organs At 
Risk (OARs), novel RT techniques have been developed. At first, the use 
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of cerrobend blocks and multileaf collimators allowed the beams to match 
or conform the outline of the target (conformal radiotherapy). Intensity-mod-
ulated radiotherapy (IMRT) is an extension of this principle. By varying the 
intensity within the radiation beam, it allows dose diversity within the same 
beam angle leading to the possibility of dose intensification or more accu-
rate shaping (even around concavities). Hence, dose distribution with IMRT 
fits more precisely to the target volume, producing a concave shape at the 
posterior aspect of the PTV, reducing dose to the rectum, and also ante-
riorly, curving around the lateral lymph node target volume while sparing 
more of the central bladder and bowel53 resulting in reduced toxicities.51 In 
cervical cancer, where the target volume has a concave shape with the 
bladder and small intestine positioned within, a large number of intensity- 
modulated beams are needed to ensure an adequate target coverage and 
sufficient sparing of the OARs. Intensity-modulated arc therapy (IMAT), 
with an infinite number of beams, is a new means to deliver IMRT. It is a 
fast and easy way to deliver a large number of beam incidences achieving 
beam intensity modulation by superimposing multiple arcs or by regulat-
ing the dose rate and the multileaf collimator movement dynamically and 
relatively to the speed of the rotating gantry.
The addition of brachytherapy during or following EBRT is still con-
sidered as a standard component of radical treatment of LACC.35, 36 
Brachytherapy involves the application of a radioactive source inside or in 
close proximity to the tumor which allows very localized irradiation resulting 
in a high dose to the tumor with relative sparing of the surrounding nor-
mal structures. Brachytherapy for cervical cancer can be performed using 
an intracavitary (placing the radioactive source into a cavity of the body, 
in this case the vagina, uterus or cervix) or interstitial approach (placing 
needles or catheters in/around tumor using a transperineal and/or vaginal 
approach). The choice of technique depends primarily on disease extent, 
anatomy and the experience in the department. In brachytherapy for cer-
vical cancer different dose regimens are used, referring to the level with 
which the radiation is delivered (expressed in Grays per hour (Gy/h)): 1) 
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Low-dose rate (LDR) brachytherapy involves implanting radiation sources 
that emit radiation at a rate of up to 2 Gy/h. 2) High-dose rate (HDR) 
brachytherapy is when the rate of dose delivery exceeds 12 Gy/h. Most 
HDR treatments are performed on an outpatient basis. 3) Pulsed-dose 
rate (PDR) brachytherapy involves short pulses of radiation, typically once 
an hour, to simulate the overall rate and effectiveness of LDR treatment. 
Overall clinical outcomes and toxicities are felt to be similar between LDR, 
HDR and PDR.54 However, a key advantage of HDR treatment is that each 
dose can be delivered on an outpatient basis with a short administration 
time providing greater convenience for many patients.
Over the last decade dramatic advances have been made in brachyther-
apy for cervical cancer. Treatment planning has evolved from two-dimen-
sional to three-dimensional, incorporating magnetic resonance imaging 
and/or computed tomography into the treatment paradigm. This allows 
for better delineation and coverage of the tumor, as well as improved 
avoidance of surrounding organs. Consequently, image guided adaptive 
brachytherapy can achieve better local control with a reduction in morbidity 
to adjacent organs such as bladder, rectum and sigmoid.55
The advantages of brachytherapy come at the expense of requiring 
an invasive procedure to be carried out, and the benefits must be bal-
anced against possible complications. Overall, in the era of image-guided 
brachytherapy, later grade >3 rectal, bowel, and bladder toxicity rates are 
typically in the 10% range.56 The probability of severe vaginal morbidity 
(grade ≥3) was around 4%. However, mild and moderate vaginal symp-
toms were still pronounced frequently (grade ≥1 around 90%; grade ≥2 
around 30%).57
2.4.3. Ghent treatment protocol for bulky  
and locally advanced cervical cancer
Since the meta-analysis of Green et al49, the combination of external beam 
radiotherapy and chemotherapy followed by brachytherapy has been 
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recommended as standard treatment for bulky IB and LACC up to stage IVA. 
Nevertheless, the meta-analysis showed a rather limited survival benefit 
for LACC in the group with FIGO stages III–IVA49, 50. Therefore, some 
groups adopted the idea of performing completion surgery after CRT. The 
rationale for performing surgery following CRT in locally advanced or bulky 
cervical cancer is to obtain a better local control by resecting potential radi-
ation therapy-resistant tumor foci. The improved local control might then 
be translated into better OS. In addition, complementary surgery permits 
the assessment of the pathological response. The concern for surgery- 
related morbidity such as fistulas and bowel or bladder injuries, however, has 
made completion surgery not widespread. The introduction of advanced 
radiation therapy techniques such as IMAT has shown to result in a better 
therapeutic ratio concerning pelvic tumors51, 58, 59.
This creates new opportunities for completion surgery. We developed 
a schedule of preoperative CRT that delivers a higher dose to the primary 
tumor and involved lymph nodes without compromising the dose to the rest 
of the clinical target volume or organs at risk. 
The treatment protocol was approved by the local ethics committee 
(referred to as n° B67020072880). Clinical staging was obtained by pel-
vic examination by an experienced gynecologic oncologist and a radia-
tion oncologist. In addition, all patients were staged by total body 18FDG 
PET-CT and pelvic magnetic resonance imaging (MRI). A panel of expe-
rienced radiologists and nuclear medicine physicians reviewed all images. 
All patients were thoroughly discussed multidisciplinary before inclusion. 
After diagnosis, patients underwent neoadjuvant IMAT, if possible com-
bined with weekly cisplatin (40 mg/m2) administration (IMAT ± C).60
After completing IMAT ± C, the possibility to perform adjuvant surgery 
was evaluated based on imaging (18FDG PET-CT and MRI) and gyneco-
logic examination. All results were multidisciplinary discussed. If considered 
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not resectable, additional brachytherapy was administered. If considered 
resectable, type II Wertheim hysterectomy ± pelvic lymphadenectomy 
was performed 4 to 6 weeks after completing IMAT ± C. Pelvic lymphaden- 
ectomy was performed whenever there were positive lymph nodes present 
on one of the 18FDG PET-CTs. From August 2008 onward, lymph node dis-
section was limited to the lymph node regions that were positive on one 
of the 18FDG PET-CTs. The reason for this change was 3-fold: first, pelvic 
lymphadenectomy after IMAT ± C only revealed histologically positive 
lymph nodes in 8.8% of the patients; second, these positive lymph nodes 
were always found in the lymph node region that was positive on the pre-
treatment PET-CT; third, some patients developed severe lymphocoeles 
and lymph edema after extensive pelvic lymphadenectomy.
In a prospective study we investigated the surgery-related morbidity 
after neo-adjuvant IMAT CRT. In addition we analyzed the value of 
a core biopsy to predict residual disease after the initial treatment.
FIGURE 2.5: Schematic representation of the treatment protocol   
(Figure courtesy K. Vandecasteele).
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Chapter 3:  
Relevance of the work
The introduction of new techniques in staging and treatment of cervical cancer 
raises questions on their overall applicability. Although advanced imaging tech-
niques have proven their value in assessing the extent of local disease and distant 
spread including lymph node invasion, results can not be included in a staging 
system as long as these tools are not widely accessible. The inclusion of its 
results would imbalance the staging system resulting in an incomparability of the 
obtained results. The success of the International Federation of Gynecology and 
Obstetrics (FIGO) clinical-based staging system of cervical cancer is due to the 
fact that it can be used worldwide without necessity of advanced imaging tech-
niques or surgical interventions. Nevertheless from an ideal staging system to be 
used in comparing treatment results and prognosis, it is expected to be reliable 
and reproducible. Although used for almost a century no data on the accuracy 
of FIGO staging are available. We looked at this topic by investigating two main 
questions:
- How reliable is clinical FIGO staging in cervical cancer?
In a prospective study we were the first to examine the interobserver 
agreement of the examination under anesthesia on which FIGO staging 
is based, in order to investigate its reliability and reproducibility (publi-
cation 1). 
- Are there patient, tumor or investigator related characteristics that 
  influence the reliability of clinical FIGO staging in cervical cancer?
We examined the impact of the experience of the investigator and patient 
specific or tumor related characteristics on the reliability of the FIGO 
staging (publication 2). Our conclusions could help to optimize staging 
in cervical cancer. 
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The standard treatment of bulky and locally advanced cervical cancer consists 
of external beam chemo-radiotherapy followed by brachytherapy. Results of this 
treatment stay disappointing. To obtain a better local control that might be trans-
lated into a better overall survival some groups had adopted the idea of perform-
ing completion surgery after chemo radiotherapy. Nevertheless there has been a 
lot of concern regarding morbidity in case of complementary surgery. The intro-
duction of advanced radiation therapy techniques (such as IMAT) significantly 
lowered grades 3 and 4 radiotherapy-related toxicity and reduced the radiation 
dose to the suspensory ligaments of the uterus. This created new opportunities 
for completion surgery. Concerning this topic we investigated following questions:
-  What is the induced per- and postoperative morbidity of completion 
surgery after IMAT+C for bulky and LACC patients? (chapter 5, pub-
lication 3). 
-  How reliable is a core biopsy in predicting residual disease after 
the initial treatment with IMAT+C for bulky and LACC patients?  
(chapter 5, publication 4).
The first author contributed to the concept and the design of the studies, patient 
selection and acquisition, analysis and interpretation of the obtained data. He 
prepared and edited all papers. 
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ABSTRACT
Objective 
The objective of this study was to assess the interobserver variability of 
pelvic examination under anesthesia (EUA) in cervical cancer.
Methods
Subsequent patients undergoing a staging procedure under anesthesia for 
primary cervical cancer were enrolled in the study. All clinicians assessed 
“blinded” tumor size, and the involvement of vagina, parametria, sacro 
uterine ligaments, pelvic sidewalls, bladder, and/or rectum. Items were 
scored varying from 1 (“certainly no involvement”), 2 (“not sure about 
involvement”), to 3 (”involvement”). Each individual decided on the Inter-
national Federation of Gynecology and Obstetrics (FIGO) stage; also, the 
urge for imaging and treatment proposal were accounted for. Final FIGO 
staging was obtained by consensus of the team. Investigators were clas-
sified as experienced after more than 50 EUAs. All others were classified 
less experienced. The free-marginal κ values between experienced and 
less experienced investigators were calculated for all previously men-
tioned items.
Results
Between February 2009 and December 2010, a total of 86 patients were 
enrolled. Among experienced investigators, a moderate interobserver 
agreement was found with regard to FIGO stage (free-marginal κ value of 
0.49) and an excellent interobserver agreement on their proposed therapy 
(free-marginal κ value of 0.84). A lower level of agreement was found when 
comparing experienced with less experienced investigators: only a slight 
level of agreement on FIGO stage and a substantial agreement on their 
therapy proposal (free-marginal κ values of 0.03 and 0.66).
Conclusions
We describe only a moderate interobserver agreement on clinical staging 
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of patients with cervical cancer. The interobserver agreement increases 
in the group of experienced doctors, indicating that EUA can be learned.
 
INTRODUCTION
Cancer of the uterine cervix is the second most common cancer in women world-
wide, and 80% of new cases are diagnosed in developing countries.1 Patients 
with cervical cancer are staged at the time of diagnosis. Cervical cancer staging 
is the oldest staging in the literature, dating back to 1928 when, for the first time, 
physicians grouped cancer of the cervix uteri into different stages according to 
the extent of tumor growth. Since then, the International Federation of Gynecol-
ogy and Obstetrics (FIGO) has developed a widely accepted staging system for 
cervical cancer. The FIGO stages are defined by tumor size and extension of 
disease beyond the cervix to adjacent tissues including vagina, parametria, sacro 
uterine ligaments, pelvic sidewalls, bladder, or rectum*.2 In this staging system, 
cervical cancer is staged predominantly by physical pelvic examination. Pelvic 
examination is ideally performed under anesthesia (EUA), which allows optimal 
clinical evaluation. Some additional examinations for establishing the stage of 
cervical cancer are allowed: hysteroscopy, cystoscopy, proctoscopy, abdominal 
ultrasound, intravenous pyelogram, and imaging with a plain radiograph of the 
lungs and skeleton. These additional tests are not mandatory for every patient. 
Results of other possible investigations such as magnetic resonance imaging 
(MRI) and positron emission tomography (PET) are not taken into account for 
FIGO staging because these imaging techniques are not widely available.
Although widely used, the reliability and reproducibility of this staging system are 
unclear. We therefore assessed the interobserver variability of EUA in cervical 
cancer. To our knowledge, this is the first article addressing this topic.
* Addition on advise of a member of the examination committee: Clinical examination, even in ideal 
circumstances, can be difficult. Tumor oedema, inflammatory changes, remnants of previous 
surgery or a recent biopsy can make it difficult to determine the exact tumor size or to evaluate 
parametrial and sidewall invasion.
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MATERIALS AND METHODS
Subsequent patients with pathological proof of cervical cancer underwent an EUA. 
During this examination, all patients were evaluated by a team of gynecologist-on-
cologists and radiotherapists. We classified doctors as experienced in this eval-
uation after more than 50 EUAs. All others were classified as less experienced. 
All involved clinicians assessed individually the tumor size (in centimeters) and 
the involvement of vagina, parametria, sacro uterine ligaments, pelvic sidewalls, 
bladder, and rectum. An involvement of these different items was scored, varying 
from 1 (“no involvement”), 2 (“not sure about involvement”) and 3 (“involvement”). 
Each individual decided on the FIGO stage and need for additional imaging, as 
well as treatment proposal. All patients were examined by at least 3 investigators, 
including at least 2 experienced investigators. Final FIGO staging was obtained 
by consensus of the team. We calculated the level of agreement for all previously 
mentioned items, first between experienced investigators and second between 
both less experienced investigators and experienced investigators. The free-mar-
ginal κ values were calculated to obtain the level of agreement on the different 
topics. For interpretation of free-marginal κ, see TABLE 1.3
RESULTS
Between February 2009 and December 2010, a total of 86 patients with cervical 
cancer were enrolled in this study. The mean age of investigated patients was 48 
years; their mean body mass index (BMI) was 26 kg/m2. Squamous cell carci-
noma was the predominant histology (76.5%). A large majority of patients were 
Level of Agreement
<0 Less than chance agreement
0.01-0.20 Slight agreement
0.21-0.40 Fair agreement
0.41-0.60 Moderate agreement
0.61-0.80 Substantial agreement
0.81-0.99 Almost perfect agreement
TABLE 1: Interpretation of free-marginal.κ3
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at advanced stage of disease (>IB1) at the time of diagnosis (69%). Patient char-
acteristics are summarized in TABLE 2. 
An analysis of the calculated free-marginal κ results demonstrate only a fair to 
moderate agreement between experienced investigators on tumor involvement 
of vagina, sacrouterine ligaments, and parametria. The agreement on tumor 
size is also moderate. Consequently, these findings result in a moderate level of 
agreement on FIGO stage. Nevertheless, these rather disappointing agreement 
levels do not reflect on the agreement on the choice of therapy, where we found 
an almost perfect level of agreement (TABLE 3). 
When calculating the agreement between an experienced investigator and a less 
experienced investigator, we found lower κ values, indicating less agreement. This 
is reflected in the fact that this comparison showed only a slight level of agree-
ment on FIGO stage. The κ value on the proposed therapy is 0.66, meaning a 
substantial agreement (TABLE 4).
Patient Characteristics n = 86 (100%)
Age, mean (range), y 48 (28-88)
Mean BMI (range), kg/m2 26 (17-40)
Tumor type, % 
Squamous cell carcinoma (SCC) 
Adenocarcinoma
76.5 
23.5
Tumor markers 
For squamous cell carcinoma 
  SCC, mean (range), mg/L 
  SCC > 2 mg/L, %
     For adenocarcinoma 
  CA-125, mean (range), U/mL 
  CA-125 > 35 U/mL, %
 
 
3.6 (0.1-233) 
31 
 
17 (9-625) 
23.5
FIGO stage (consensus), % 
Stage IA1 
Stage IA2 
Stage IB1 
Stage IB2 
Stage IIA1 
Stage IIA2 
Stage IIB 
Stage IIIIA 
Stage IIIB 
Stage IVA 
Stage IVB
0 
1.2 
29.1 
7 
3.5 
1.2 
45.4 
0 
8.1  
4.5  
0
TABLE 2: Patients characteristics.
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Of all patients considered suitable for primary surgery, 21 patients were operated 
on (24% of all patients). In 14 patients (66.7%), pathological results were similar 
to FIGO staging (consensus FIGO stage), and no involved pelvic lymph nodes 
were detected. In 7 patients (33. 3%), there was either a tumoral involvement of 
the parametrium or sacrouterine ligaments (2 patients) or an involvement of lymph 
nodes (3 patients) or both (2 patients). This means that, first, in 4 of these 21 
Free-Marginal κ p Interpretation of κ:  Level of Agreement
FIGO stage 0.03 < 0.01 Slight agreement
Proposed therapy 0.66 < 0.01 Substantial agreement
TABLE 4:  Agreement on EUA by experienced investigator versus nonexperienced investigator.
Free-Marginal κ p Interpretation of κ:  Level of Agreement
Size of the tumor 0.42 0.07 Moderate
Vaginal < ½ involvement 0.57 < 0.01 Moderate
Vaginal > ½ involvement 0.47 0.01 Moderate
Sacrouterine ligament right  
< ½ involvement 0.32 0.01 Fair
Sacrouterine ligament right  
≥ ½ involvement 0.46 0.02 Moderate
Sacrouterine ligament left  
< ½ involvement 0.38 < 0.01 Fair
Sacrouterine ligament left  
≥ ½ involvement 0.25 0.05 Fair
Parametrium right  
< ½ involvement 0.43 < 0.01 Moderate
Parametrium right  
≥ ½ involvement 0.42 < 0.01 Moderate
Parametrium left  
< ½ involvement 0.38 < 0.01 Fair
Parametrium left  
≥ ½ involvement 0.31 < 0.01 Fair
Rectum involvement 1 0.08 Perfect
FIGO stage 0.49 < 0.01 Moderate
Proposed therapy 0.84 < 0.01 Almost perfect
Request for additional imag-
ing test (MRI) 0.84 < 0.01 Almost perfect
TABLE 3:  Free κ value on all different scored items of the EUA when the results of 3 experienced 
investigators were compared.
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patients (19%), the tumor spread beyond cervix and uterus was not predicted by 
clinical staging and, second, that in 5 (24%) of these operated patients, positive 
lymph nodes were detected (FIGURE 1). Characteristics of patients operated on 
with positive lymph nodes are summarized in TABLE 5.
FIGURE 1: Results of patients operated on.
14 surgical staging = 
Preoperative FIGO staging 
66,7%
2 only local spread beyond uterus 
No lymph node invasion
3 local spread beyond uterus 
and lymph node invasion
2 lymphnode invasion 
No local spread beyond uterus
7 surgical staging = 
Preoperative FIGO staging 
33,3%
21 patients operated
FIGO 
Stage
Preoperative 
Imaging
No.  
Removed 
Lymph  
Nodes
No.  
Positive 
Lymph 
Nodes
Localization of the  
Positive Lymph Nodes
Maximal  
Size of  
Metastasis
Patient 1 IB1 No 57 2 Right obturator fossa (1) 
Left common iliac artery (1)
4 mm
Patient 2 IB1 No 20 2 Right external iliac artery (1) 
Left internal iliac artery (1)
Not reported
Patient 3 IB1 No 28 1 Left obturator fossa (1) Micro  
metastasis
Patient 4 IB1 No 34 5 Right common iliac artery (2) 
Right external iliac artery (2) 
Left obturator fossa (1)
Not reported
Patient 5 IB1 No 37 1 Right external iliac artery (1) 5 mm
TABLE 5: Characteristics of operated patients with positive lymph nodes.
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DISCUSSION
The success of clinical-based cervical cancer FIGO staging is mainly built on 
the fact that it can be used worldwide to stage new patients without necessity of 
advanced imaging techniques or surgical interventions. This is particularly import-
ant because 80% of new cervical cancers are diagnosed in low resource coun-
tries.1 Cervical cancer FIGO staging aids in treatment decisions, can be used to 
assess the response to treatment, gives information about prognosis, and is at 
present the uniform format for the description of disease to exchange and com-
pare information. Although limitations of FIGO clinical staging are also well appre-
ciated, to our knowledge this is the first article addressing its reliability and repro-
ducibility. Tumor size, parametrial invasion, and sidewall invasion can be difficult to 
assess accurately by clinical examination or by FIGO-approved additional tests. 
These findings are reflected in the level of agreement of experienced investiga-
tors on these items as calculated in our study. The low κ values indicate a fair to 
moderate agreement on these items. In literature, it stays controversial whether 
additional imaging techniques (MRI, computed tomography [CT]) are more accu-
rate than clinical examination alone to assess tumor size or local spread.4,5 In a 
recent meta-analysis by Thomeer et al,6 imaging is shown to be superior to EUA 
to assess tumor status*.
Nevertheless, we see that when available additional testing modalities are fre-
quently used to evaluate women with cervical cancer. The results of these tests 
are used for planning treatment but do not influence FIGO stage.
The disagreement on local spread logically results in a moderate level on agree-
ment of FIGO stage, although this has little effect on the choice of therapy where 
an almost perfect agreement was found. This can be explained by the fact that at 
present in the most standard treatment protocols7,8 of cervical cancer there are few 
therapeutic options: (1) surgery is typically reserved for lower-stage disease and 
smaller lesions, such as stages IA, IB1, and selected IIA1; (2) concurrent chemo-
radiation is the primary treatment of choice for stages IB2-IVA; it can also be used 
* Change on advise of a member of the examination committee: change “tumor status” to “tumor volume”.
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for patients who are not candidates for surgery; (3) those patients with widely 
metastatic disease (stage IVB) are typically treated with full-dose chemotherapy 
alone or in addition with palliative radiation to reduce bleeding and pain. Future 
new insights in the pathology and evolutions in treatment of cervical cancer (such 
as additional hyperthermia,9,10 neoadjuvant chemotherapy,11 and advanced radio-
therapy techniques12) could result in a wider spread of treatment options, making 
precise staging more important to decide on individualized therapy.
Some patient or tumor characteristics (such as BMI and size of the tumor) could 
influence the interobserver variability of an EUA. A much larger study population 
is needed to distinguish influencing characteristics.
The clinical staging system for cervical cancer is limited to the specified set of 
examinations and does not assess the full extent of disease in all women. This 
leads to understaging of some patients, resulting in suboptimal treatment. In our 
series of all patients operated on, 33% were understaged by clinical-based FIGO 
staging.
In FIGO staging, no consideration is taken to lymph node metastasis, although 
it is associated with a worse prognosis.13 Because of the lack of screening pro-
grams and health care facilities, the vast majority of cervical cancers in develop-
ing countries are diagnosed at an advanced stage. Therefore, the lymph node 
assessment could be considered less important, because they more likely to be 
positive in advanced stages and of less impact on therapy choices and progno-
sis. In industrialized countries with better organized health care systems, cervical 
cancer often is diagnosed in earlier stages. Lymph node invasion has an impact 
on therapeutic decision making. Historically, surgery with lymphadenectomy was 
required to evaluate for lymph node metastases; nowadays, options for evaluating 
for lymph node metastases include also imaging studies (CT, PET, or PET-CT).14 
Malignant lymph node involvement was detected in 24% of patients who were 
operated on in our study. No PET or PET-CT was performed before surgery in 
these cases.
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The FIGO staging system is largely based on physical examination. Our data 
show a better interobserver agreement between experienced investigators when 
compared with less experienced doctors. This indicates that there is a learning 
process for EUA, and therefore an examination by an experienced examiner is 
more reliable. In addition, the learning time of an EUA is very much dependent 
on availability of patients, whereas nowadays the tumor assessment by imaging 
techniques can be trained on reproducible examples.
CONCLUSIONS
In our study, a moderate interobserver agreement on clinical staging of patients 
with cervical cancer is described. Examination under anesthesia can be learned, 
because interobserver variability decreases in the group of experienced doctors.
REMARK: The text is identical to the one published in the journal.
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ABSTRACT
Background
The International Federation of Gynecology and Obstetrics (FIGO) Cervical 
cancer staging system is based on a clinical gynecological examination. 
Although widely used, no data are available on its reliability and reproduc-
ibility. We investigated the inter observer agreement (IOA) of this staging 
system and its confounding factors.
Methods 
From February 2009 to October 2012 patients undergoing clinical cervical 
cancer staging were included. Patients were examined by 2 experienced 
(and often 1 inexperienced) investigators independently. Each investiga-
tor assessed the FIGO stage and defined a treatment proposal. The inter- 
observer agreement was operationalized through the unweighted Cohen’s 
κ coefficient. A multivariate analysis was used to evaluate the impact of 
patient and tumor characteristics on the IOA of FIGO staging. 
Findings
155 patients were enrolled. Among experienced investigators, a moder-
ate IOA was found with regard to FIGO stage (κ = 0.64 (0.052)) and an 
excellent IOA on their proposed therapy (κ = 0.87 (0.042)). No significant 
impact of BMI, age, tumor type or level of tumor markers on the IOA could 
be demonstrated. The IOA between 2 experienced investigators differed 
from the IOA among experienced and inexperienced investigators concern-
ing stage of disease (significant) and choice of therapy (almost significant).
Conclusions 
The IOA on clinical cervical cancer staging is moderate. On the contrary 
the IOA for choice of treatment is excellent. The IOA on tumor stage and 
choice of therapy was best among experienced investigators, indicating 
the importance of centralization of care. No confounding patient or tumor 
related characteristics were demonstrated. 
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INTRODUCTION
Cancer of the cervix uteri is the fourth most common malignancy to affect women. 
In 2012 528,000 new cases of cervical cancer were reported worldwide with an 
estimated 266,000 deaths, representing 7.5% of all female cancer deaths. About 
85% of the global burden occurs in less developed countries, where it accounts 
for almost 12% of all female cancers1. The limited access to cytological screen-
ing in these countries results in delayed diagnosis and more advanced stage dis-
eases. In addition, prospects for treatment of advanced disease are poor, result-
ing in a high rate of death from cervical cancer.2,3 
Determination of optimal treatment in cervical cancer patients is mainly based on 
an accurate assessment of the extension of the disease. The extension of cer-
vical cancer at time of diagnosis is expressed following the definitions adopted 
by the International Federation of Gynecology and Obstetrics (FIGO) originated 
in the work of the cancer commission of the Health Organization of the League 
of Nations first published in 1920.4 This classification was designed to mimic the 
natural history of the disease where the different stages represent the progres-
sive growth of the tumor. Over the years the FIGO Committee on Gynecologic 
Oncology has made several modifications to the classification system of cervical 
cancer but it is still mainly based on the clinical gynecological examination evalu-
ating the anatomic extent of the disease. FIGO stages are defined by tumor size 
and extension of disease beyond the cervix (vagina, parametria, sacro - uter-
ine ligaments, pelvic side walls, bladder, rectum or distant metastasis). The last 
classification revision dates from 2009.5 According to the current FIGO staging 
guidelines, findings on clinical examination (ideally performed under anesthesia) 
can be supplemented by few diagnostic tools: hysteroscopy, cystoscopy, proc-
toscopy, abdominal ultrasound, intravenous pyelogram (IVP) and imaging with 
a plain radiograph of the lungs and skeleton. Results of more advanced radio-
logic techniques as Magnetic Resonance Imaging (MRI) and Positron Emission 
Tomography (PET) are not taken in account for staging. This is because of the 
limited accessibility to such techniques in developing countries where most cases 
of cervical cancer are diagnosed nowadays. 
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One of the major purposes of cancer staging is to offer a classification of a can-
cer’s extent in order to provide a method for comparing treatment results. To 
achieve this objective the quality, reliability and reproducibility of the staging sys-
tem is crucial.
In a previous preliminary report we addressed the interobserver variability of the 
examination under anesthesia (EUA) in cervical cancer.6 We documented only 
a moderate interobserver agreement in clinical staging of cervical cancer when 
results of independent experienced clinicians were compared. 
In the present report, based on a larger sample we investigated the influence 
of multiple characteristics (experience of the investigator and patient or disease 
related characteristics) on the interobserver agreement of the clinical FIGO stag-
ing of cervical cancer. To our knowledge this is the first study addressing this topic. 
MATERIALS AND METHODS 
All subsequent patients with primary cervical cancer diagnosed and staged at the 
Erasmus MC Cancer Institute (Rotterdam, The Netherlands) between February 
2009 and October 2012 were included in the study. The clinical staging was per-
formed under general anaesthesia. Patient’s characteristics were prospectively 
documented. During the procedure all patients were examined independently by 
at least 2 experienced investigators. When present, patients were also examined 
by an inexperienced practitioner. Investigators were classified as experienced 
after more than 50 Examinations Under Anesthesia (EUA). All clinicians scored 
the examination independently on different staging related topics: tumor size and 
the involvement of vagina, parametria, sacro - uterine ligaments, pelvic side walls, 
bladder, and / or rectum. All items were scored on a 3-point scale varying from 
1 “certainly no involvement”, 2: “not sure about involvement” and 3:”involvement”. 
Finally each investigator was asked to appoint the FIGO stage and to propose a 
therapy (1: surgery, 2: (chemo) radiotherapy or 3: other treatment). For statistical 
evaluation FIGO stages were grouped in 5 categories (I, IIA, IIB, III, IV)
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STATISTICAL METHODS
Results were expressed as means (standard deviations) for quantitative variables, 
while frequencies and proportions (%) were used for categorical variables. 
The inter-observer agreement on each item was calculated through the 
unweighted Cohen’s κ coefficient using a Bayesian multilevel approach. Cohen’s 
κ coefficient was chosen instead of a weighted kappa coefficient to reflect the 
practice reality that all disagreements are of equal importance. The maximum 
likelihood estimator of Cohen’s kappa coefficient was not appropriate since a 
random pair of practitioners, differing from patient to patient, examined each 
patient. Therefore, the practitioners have to be considered as random rather than 
fixed. The method described in Vanbelle et al. (2012)7 was therefore used. We 
assumed non-informative priors, which express that we do not have prior infor-
mation on the parameters. For the regression coefficients, vague independent pri-
ors were assumed to follow a normal distribution with mean 0 and large variance, 
i.e. N(0,100). The prior distribution for all the standard deviations of the observer 
random effects was taken as uniform [0,100]. Three parallel Markov-Chain Monte 
Carlo (MCMC) chains were run, each for 30000 iterations for all the models with a 
burn in period of 2500 iterations. The convergence of these MCMC was checked 
using the CODA package in R. In particular, we used the Gelman and Rubin’s 
diagnostics measure R and this value was close to 1 for all the parameters, which 
means there was no evidence against convergence. The same method was used 
to study the effect of the practitioner’s experience on the agreement level by 
comparing the agreement level between the two experienced examiners with the 
agreement level between inexperienced and experienced practitioners. Finally, we 
studied the influence of patient and tumor characteristics on the agreement level 
between the two experienced investigators. Before performing a multivariate anal-
ysis, the influence of each characteristic was considered separately. Documented 
characteristics were age and BMI of the patient, tumor histology (squamous cell 
carcinoma or adeno carcinoma) and level of specific tumor marker (Squamous 
Cell Carcinoma antigen (SCC-ag) (ng/mL) in squamous cell carcinoma, Cancer 
Antigen 125 (CA125) (U/ml) in adeno carcinoma).
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Calculations were always carried out on the maximum number of data available. 
Missing data were not replaced. The posterior distribution of the κ coefficient was 
summarized using a 95% credibility interval (95% CI). Data analysis was carried 
out using R (version 3.0.2 for Windows) and Winbugs statistical packages.
 
RESULTS
Between February 2009 and October 2012 a total 155 subsequent patients with 
cervical cancer undergoing an EUA were enrolled in this study. Average age was 
52.7 (SD: 15.1) years with a mean BMI of 26.2 (SD: 5.1) kg/m². The histology was 
predominantly squamous cell carcinoma (79.4%), followed by adenocarcinoma 
(20.6%). The vast majority of patients (71.7 %) were diagnosed with an advanced 
stage of disease (> FIGO IB1), as agreed on by consensus between investigators. 
Patient characteristics are summarised in TABLE 1.
Patients characteristics n Frequency (%)
Age (years) 155 52.7 (15.1) [27-88]
BMI (kg/m²) 146 26.2 (5.1) [17-41]
Tumor type 155
      Sqamous cell carcinoma 123 79.4 %
      Adenocarcinoma 32 20.6 %
Tumor markers 126
      For squamous cell carcinoma
         SCC, mean (range), mg/L 2.9 (0.1 - 233)
         SCC > 1,9 mg/L % 61.6 %
      For adenocarcinoma
         CA-125, mean (range), U/mL 25 (9 - 625)
         CA-125 > 35 U/mL, % 23.1 %
FIGO Stage (consensus), %
      Stage IA1 0 0 % 
      Stage IA2 1 0.6 %
      Stage IB1 43 27.7 %
      Stage IB2 10 6.5 %
      Stage IIA1 7 4.5 %
      Stage IIA2 2 1.3 %
      Stage IIB 69 44.6 %
      Stage IIIA 3 1.9 %
      Stage IIIB 8 5.2 %
      Stage IVA 11 7.1 %
      Stage IVB 1 0.6 %
TABLE 1:  Patients characteristics. Results are expressed as Mean (SD) [range] for quantitative vari-
ables and frequency (%) for qualitative variables. SCC > 1.9 or CA 125 > 35 are indicative 
for imaging in clinically low stage disease
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The agreement level between the two experienced examiners on staging related 
topics is given in TABLE 2. Cohen’s κ coefficient was the largest on tumor size 
and therapy. Agreement was less satisfactory regarding tumor involvement of 
sacro uterine ligaments and parametria. Finally, the agreement level on rectal 
invasion was not larger than chance due to the large asymptotic standard error 
(ASE). Note that 97% of the patients were negative for rectal invasion. Despite 
a moderate level of agreement on FIGO stage, the agreement on the proposed 
therapy was almost perfect.
 
Sample size κ 95% CI
size of the tumor 144 0.72 (0.048) 0.62-0.81
vaginal involvement 154 0.54 (0.061) 0.41-0.65
sacro uterine ligament right involvement 155 0.29 (0.092) 0.092-0.46
sacro uterine ligament left involvement 155 0.40 (0.072) 0.24-0.53
parametrium right involvement 155 0.42 (0.072) 0.28-0.56
parametrium left involvement 155 0.43 (0.069) 0.29-0.56
rectum involvement* 155
0.36 
(0.41) -0.69-0.82
FIGO STAGE (5 categories**) 155 0.64 (0.052) 0.53-0.74
proposed therapy 155 0.87 (0.042) 0.77-0.93
TABLE 2:  Posterior distribution of the Cohen’s kappa coefficient, (mean SD) and 95% credibility 
interval between pairs of experienced investigators 
*97% of the patients are negative. 
** Stage I, IIA, IIB, III, IV 
A subset of 111 patients was examined by one inexperienced and two experi-
enced investigators. The agreement level between inexperienced and experienced 
examiners on the FIGO staging was significantly lower compared to the agree-
ment level between two experienced examiners (0.34 (95% CI: 0.23-0.44) versus 
0.59 (95% CI: 0.46-0.71)). The disagreements between the inexperienced and the 
experienced examiners were mainly situated in cases where the inexperienced 
practitioner rated the FIGO stage to be lower than the experienced examiner. 
There was no such particular disagreement pattern between the two experienced 
examiners. The agreement level between an inexperienced and an experienced 
examiner on the therapy was lower than the agreement level between two expe-
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rienced examiners (0.58 (95% CI: 0.45-0.69) versus 0.81 (95% CI: 0.66-0.91)). 
Most of the disagreements between the inexperienced and the experienced 
examiners occurred when the inexperienced examiner recommended surgery 
while the experienced examiner recommended (chemo) radiotherapy. There was 
no disagreement pattern between the two experienced examiners.
Univariate and multivariate regression analysis showed no effect of patient and 
tumor characteristics on the agreement level amongst the two experienced 
examiners. The results were similar for the univariate and multivariate approach. 
Results are presented in TABLE 3.
Variable Means (SD) (P2.5-P97.5) Means (SD) (P2.5-P97.5)
Model for the marginals*
Intercept 1 0.32 (0.39) (-0.44-1.07) 0.82 (0.51) (-0.16-1.86)
Intercept 2 0.47 (0.39) (-0.30-1.22) 0.99 (0.51) (0.0081-2.01)
Intercept 3 1.84 (0.41) (1.04-2.62) 2.41 (0.53) (1.39-3.47)
Intercept 4 2.42 (0.42) (1.59-3.22) 3.20 (0.54) (2.15-4.28)
Age 0.020 (0.0046) (0.011-0.029) 0.019 (0.0051) (0.0084-0.029)
BMI -0.021 (0.012) (-0.044-0.0023) -0.0075 (0.016) (-0.039-0.024)
Marker(1)
       <=2 normal values - 0.80 (0.23) (0.35-1.25)
       >2 normal values - 0.81 (0.16) (0.49-1.13)
Histology (2)
        SCC 0.32 (0.17) (-0.0078-0.66) -
s² 0.017 (0.026) (0.00-0.087) 0.013 (0.025) (0.00-0.083)
Cohen’s kappa coefficient**
Intercept 0.45 (0.61) (-0.67-1.67) 0.55 (0.65) (-0.74-1.82)
Age 0.00061 (0.0061) (-0.011-0.013) 0.0015 (0.0066) (-0.011-0.014)
BMI 0.0021 (0.018) (-0.033-0.038) 0.0078 (0.020) (-0.031-0.048)
Marker(1)
       <=2 normal values - -0.15 (0.31) (-0.75-0.49)
       >2 normal values - -0.29 (0.23) (-0.74-0.15)
Histology (2)
        SCC 0.22 (0.22) (-0.23-0.65) -
TABLE 3: Summary of the posterior distribution of the model parameters (mean (SD) (95%CI)) cor-
responding to the marginal and kappa model when histology of the tumor (left) of the level 
of the tumor (right) is included in the model
*The model for the marginal is (j=1,…,4)  
  where ηr is a random effect normally distributed with mean 0 and variance relative to the  
  examiners (r=1,…,21). 
** The model for Cohen’s kappa coefficient is:  
(1) Normal value is taken as reference category
(2) Adenorcarcinoma is taken as reference category
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Patients with a consensus FIGO stage < IIB and < 4 cm, with normal tumor 
markers and (if performed) normal imaging were evaluated for surgery. Of all 
patients, thirty-five were operated on (22,6% of all patients). In 77.1% (n= 27) of 
surgically treated patients the preoperative FIGO stage was comparable with the 
postoperative pathological TNM classification (pTNM). In eight patients (22.9%) 
the FIGO differed from the pTNM. In five patients the pT was upstaged (14.3%), 
in 6 patients (17.2%) malignant lymph nodes were present. Findings of operated 
patients are documented in FIGURE 1.
FIGURE 1: Results of patients operated on.
 
DISCUSSION 
Prognosis and treatment decisions in cervical cancer patients are based on size 
and extent of the disease mainly estimated by clinical examination and classified 
according to FIGO staging system.8 This staging system can also be seen as a 
common international language for information sharing and results comparing. 
Since supplementary information from advanced radiologic techniques are not 
permitted in the current cervical cancer FIGO staging5, the clinical gynecologi-
cal examination on which FIGO staging is based, needs proof of reliability and 
reproducibility. To our knowledge we are the first to address these issues by 
investigating its IOA. 
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Our results showed a moderate inter-observer agreement between two experi-
enced investigators on the FIGO stage indicating a possible limitation for sharing 
and comparing results based on this staging system. 
At present time the therapeutic impact of the moderate agreement on FIGO 
stage seems to be limited since we found an almost perfect inter-observer agree-
ment between two experienced examiners on treatment proposal. This can be 
explained by the fact that currently only few therapeutic options are considered 
as standard treatment9,10: 1) surgery as primary option for early stage non-bulky 
disease and 2) chemo radiation for more advanced disease. Future therapeutic 
options based on surgical evolutions (f.e. applicability of sentinel node procedure, 
a tailored extension of radical surgery, fertility preserving treatment…), progress 
in systemic treatment (f.e. chemotherapy in advanced cervical cancer…) and the 
introduction of advanced radiotherapeutic tools will result in a more differentiated 
and individualized care. It is possible that with an increase in therapeutic options, 
the level of agreement on treatment proposal based on a clinical gynecological 
examination would decrease and become comparable to the level of agreement 
on FIGO stage. 
In this study multivariate analysis showed no significant impact of BMI, age, 
tumor histology or level of the specific tumor markers on the IOA of FIGO stage. 
It is important to stress that all exams were performed under general anesthe-
sia. These findings implicate that BMI has no major impact on accuracy of clini-
cal staging when it is performed by experienced gynecologic / radiotherapeutic 
oncologist under optimal condition including general anesthesia. 
Not only is an EUA used for clinical staging of cervical cancer but it also provides 
an opportunity for obtaining an adequate biopsy of the tumor for further patho-
logical typing and it facilitates the introduction of radiological markers to delineate 
the tumor which can help in radiotherapy planning.
We demonstrated a significant better agreement concerning FIGO stage be- 
tween experienced investigators when compared with an experienced and an 
58
inexperienced investigator. This implicates that clinical examination is a matter of 
training that is normally available within high volume hospitals. Besides, one could 
stipulate that at least one experienced clinician should stage patients in order to 
obtain the best possible clinical staging.
A close look on the disagreements patterns on FIGO stage between the inexpe-
rienced and the experienced examiners showed that in case of discrepancy the 
inexperienced investigator tended to underestimate the disease stage (by rating 
the FIGO stage to be lower than the rating of the experienced examiner). No 
such disagreement pattern between the two experienced examiners was found.
Our results also showed that the underestimation of disease stage by the inex-
perienced compared to the experienced examiner resulted consequently in a 
lower level of agreement concerning the choice of therapy that almost reached 
a significant value. Most of the disagreements between the inexperienced and 
experienced examiner occurred when the inexperienced examiner recommended 
surgery in patients with more advanced stage that were considered inoperable by 
the experienced examiner. This implies a potential risk of suboptimal surgeries, 
with positive surgical margins and subsequent indications for adjuvant radio- 
therapy. Overall resulting in a suboptimal treatment with an increased risk of 
morbidity and higher medical costs.11,12 We found no such disagreement pattern 
between the two experienced examiners.
The differences in agreement among experienced versus inexperienced and 
among experienced investigators concerning stage of disease and choice of ther-
apy are important arguments favoring centralization of care, also in low resource 
countries. 
* Addition on advise of a member of the examination committee: Our data on operated patients (figure 
1) demonstrate that of the 35 patients that were estimated eligible for Wertheim surgery, in 27 the 
postoperative pathological classification (pTNM) was comparable to the preoperative FIGO-classifi-
cation. In more than 1/5 patients additional pre-operative staging techniques (such as MRI, PET-CT) 
could have adjusted the treatment directly towards chemoradiotherapy.
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CONCLUSIONS
We found a moderate inter observer agreement on the clinical staging of cervical 
cancer. We were unable to demonstrate any patient or tumor related character-
istics that have an impact on the inter observer agreement of this clinical staging. 
We found differences in agreement between experienced versus inexperienced 
and two experienced investigators concerning stage of disease (significant differ-
ence) and choice of therapy (almost significant difference), indicating the impor-
tance of centralization of cervical cancer care. 
REMARK: the text is identical to the one submitted to the journal.
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ABSTRACT
Introduction
Since the addition of chemotherapy to radiotherapy, the survival rates of 
locally advanced cervical cancer (LACC) have improved but are still dis-
appointing. Therefore, the idea of surgery after chemoradiation in case 
of LACC or bulky disease was adopted. One of the concerns regarding 
surgery following chemoradiotherapy is surgery-related morbidity.
Aim
The objectives of this study were to investigate the feasibility of surgery 
after advanced radiotherapy techniques such as intensity-modulated arc 
therapy (IMAT) and to describe the morbidity.
Methods
This was a prospective study of primary inoperable LACC patients primary 
treated with IMAT, in most cases combined with weekly cisplatin. Then 
the resectability was reevaluated. If resectable patients were treated with 
Wertheim type 2 surgery ± pelvic lymphadenectomy (on positron emission 
tomography–computed tomography indication). If tumor was not resectable, 
patients were treated with brachytherapy.
Results
Since 2006, 41 consecutive patients were included. After neoadjuvant IMAT, 
34 were considered resectable and underwent surgery, whereas 7 pro-
ceeded with brachytherapy. The operative mortality rate was nil. There were 
no major perioperative complications. No ureter, bladder, or bowel injuries 
occurred. No postoperative urinary/digestive fistulae or stenoses were 
noted. Eleven patients had postoperatively urinary retention problems. At 
the time of discharge, 5 patients still needed self-catheterization. All prob-
lems resolved within 3 months. In 4 cases, we saw significant lymphoceles. 
In all patients intended to treat, overall survival and disease-free survival 
at 3 years were 63% and 74%. In the Wertheim group, overall survival and 
disease-free survival at 3 years were 81% and 91%.
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Conclusions
Completing surgery after chemoradiation therapy (with IMAT) for LACC or 
bulky disease is feasible, and complication rates are comparable with those 
of primary surgery for cervical cancer.
INTRODUCTION
Cancer of the uterine cervix is the second most common cancer in women world-
wide, and 80% of new cases are diagnosed in developing countries. Although the 
incidence of invasive cervical cancer has decreased in industrialized countries 
because of screening programs and management of intraepithelial lesions, 60% 
of cases are already at advanced stages at the time of diagnosis. This incidence 
is even higher in developing countries.1 Management of patients with cervical 
cancer depends on the stage of disease at diagnosis, based on the International 
Federation of Gynecology and Obstetrics (FIGO) staging system. Since the 
meta-analysis of Green et al,2 the combination of external beam radiotherapy 
(EBRT) and chemotherapy (CRT) followed by intracavitary brachytherapy has 
been recommended as standard treatment for bulky IB and locally advanced cer-
vical cancer (LACC) up to stage IVA. Nevertheless, the meta-analysis showed a 
rather limited survival benefit for LACC in the group with FIGO stages III–IVA and 
remained disappointing. Therefore, some groups adopted the idea of performing 
completion surgery after chemoradiation. The rationale for performing surgery 
following chemoradiation in locally advanced or bulky cervical cancer is to obtain 
a better local control that might translate into better overall survival (OS), because 
surgery allows the removal of potential radiation therapy–resistant tumor foci.
In addition, it permits the assessment of the pathological response. The concern 
for surgery-related morbidity such as fistulas and bowel and bladder injuries, 
however, has made completion surgery not widespread. Advanced radiation 
therapy such as intensity-modulated radiotherapy has shown to result in a bet-
ter therapeutic ratio concerning pelvic tumors.3,4 Intensity-modulated arc therapy 
(IMAT), with an infinite number of beams, is a new means to deliver IMRT. In cer-
vical cancer, where the target volume has a concave shape with the bladder and 
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small intestine positioned within, a large number of intensity-modulated beams 
are needed to ensure an adequate target coverage and sufficient sparing of 
organs at risk.
The introduction of these advanced radiotherapy techniques creates new oppor-
tunities for completion surgery. We developed a schedule of preoperative CRT 
that delivers a higher dose to the primary tumor and involved lymph nodes with-
out compromising the dose to the rest of the clinical target volume or organs at 
risk. We previously reported on the rationale, feasibility, toxicity, and oncologic 
results of neoadjuvant IMAT followed by hysterectomy in the treatment of FIGO 
IB2 (bulky)–IVA tumors.4,5 This report evaluates the surgical morbidity on this 
multimodality treatment.
 
MATERIALS AND METHODS
This prospective study was approved by the local ethics committee, referred to as 
n° B67020072880. Inclusion criteria were biopsy-proven locally advanced (FIGO 
IB2-IVA) cervical cancer (LACC), absence of distant metastases and extrapelvic 
lymph node(s) as diagnosed on fluorine 18 fluorodeoxyglucose (18FDG) positron 
emission tomography–computed tomography (PET-CT), World Health Organiza-
tion score 0–2; ability to understand and sign informed consent, and absence of 
any condition potentially obstructing compliance with the follow-up schedule and 
study protocol.
Clinical staging was obtained by pelvic examination by an experienced gyneco-
logic oncologist and a radiation oncologist. In addition, all patients were staged 
by total body 18FDG PET-CT and pelvic magnetic resonance imaging (MRI). A 
panel of experienced radiologists and nuclear medicine physicians reviewed all 
images. All patients were thoroughly discussed multidisciplinary before inclusion. 
Patient characteristics are summarized in TABLE 1.
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After diagnosis, patients underwent neoadjuvant IMAT, if possible combined with 
weekly cisplatin administration (IMAT ± C). Details concerning delineation, dose 
description, planning, and delivery of IMAT were previously reported.4
After completing IMAT ± C, the possibility to perform adjuvant surgery was eval-
uated based on imaging (18FDG PET-CT and MRI) and gynecologic examination. 
All results were multidisciplinary discussed. If considered resectable, type II Wert-
heim hysterectomy ± pelvic lymphadenectomy was performed 4 to 6 weeks after 
completing IMAT ± C. Pelvic lymphadenectomy was performed whenever there 
were positive lymph nodes present on one of the 18FDG PET-CTs. From August 
2008 onward, lymph node dissection was limited to the lymph node regions that 
 
Overall Operated Not Operated
No. (%) patients 41 34 (82.9%)   7 (17.1%)
Mean age (range), y 53 (26-80) 52 (26-80) 57 (45-80)
Karnovsky score, % (n) 
70 
80 
90 
100
 
  4.9 (2) 
14.6 (6) 
56.1 (23) 
24.4 (10)
 
  2.9 (1) 
11.8 (4) 
58.8 (20) 
26.5 9)
 
14.3 (1) 
28.6 (2) 
42.8 (3) 
14.3 (1)
Histology, % (n) 
Squamous cell carcinoma 
Adenocarcinoma
90.2 (37) 
  9.8 (4)
88.2 (30) 
11.8 (4)
100 (7) 
0 (0)
FIGO, % (n) 
IB2 
IIB 
IIIA 
IIIB 
IVA 
IVB
 
  7.3 (3) 
58.6 (24) 
  9.8 (4) 
14.6 (6) 
  7.3 (3) 
  2.4% (1)
 
  8.8 (3) 
64.6 (22) 
  8.8 (3) 
11.8% (4) 
  2.9 (1) 
  2.9 (1)
 
0 (0) 
28.5 (2) 
14.5 (1) 
28.5 (2) 
28.5 (2) 
0 (0)
Grade, % (n) 
Grade 1 
Grade 2 
Grade 3
 
  4.9 (2) 
51.2 (21) 
43.9 (18)
 
  5.8 (2) 
47.1 (16) 
47.1 (16)
 
0 (0) 
71.4 (5) 
28.6 (2)
Average diameter (range), cm   5.5  
 (2.3 -7.5)
  5.3  
 (2.3 - 7.5)
  5.8 
 (5.0-7.5)
PET + ln, % (n) 39.0 (16/41) 38.2 (13/34) 42.8 (3/7)
Chemotherapy associated with radiotherapy, % (n) 82.9 85.3 (29) 71.4 (5)
Clinical complete response to IMAT + C, % (n) 80.5 (33) 97.1 (33/34) 0 (0/7)
TABLE 1: Patients characteristics.
66
were positive on one of the 18FDG PET-CTs. The reason for this change was 
3-fold: first, pelvic lymphadenectomy after IMAT ± C only revealed histologically 
positive lymph nodes in 8.8% of the patients; second, these positive lymph nodes 
were always found in the lymph node region that was positive on the pretreatment 
PET-CT; third, some patients developed severe lymphoceles and lymph edema 
after extensive pelvic lymphadenectomy.
The protocol excluded the following patients from adjuvant hysterectomy:
(1) evidence of local progression,
(2) insufficient response on clinical examination and MRI  
     (defined as tumor shrinkage by <50%),
(3) development of distant metastasis (PET-CT),
(4) insufficient general condition to undergo hysterectomy, or
(5) patient’s refusal.
These patients with a poor prognosis would benefit only from large (exenteration) 
surgery and therefore, taking into account their quality of life, were treated with 
an additional brachytherapy.
Postoperative morbidity was prospectively examined and registered. A standard 
postoperative schema was used to register complains and morbidity. Postopera-
tive period was defined as up to 6 weeks’ postsurgical intervention.
 
Registration of Surgical Morbidity
Surgical morbidity/mortality was evaluated and registered during hospitalization 
(acute) and at every visit thereafter (late) and was classified according to the 
Chassagne grading system.6 The postoperative period was considered as up to 
6 weeks’ postsurgical intervention.
After patients were discharged from the hospital, the first follow-up at the outpa-
tient clinic was scheduled 6 weeks after surgery. Thereafter, follow-up was sched-
uled 3-monthly for the first 2 years after treatment and from then 6-monthly. The 
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follow-up was performed at a multidisciplinary consultation (by both a gynecologic 
oncologist and a radiation oncologist). Local and distant control was evaluated 
at every visit by gynecologic and general clinical examination. Imaging (18FDG 
PET-CT and MRI) was performed every 6 months for the first 2 years and yearly 
thereafter, or on symptoms.
RESULTS
Patients
Between September 2006 and August 2011, 41 consecutive patients 
with LACC were included in this study. Patient characteristics are summa-
rized TABLE 1. The mean age at diagnosis was 53 years (range, 26–80 
years). Squamous cell carcinoma was the predominant histology (90.2%). 
All enrolled patients completed IMAT, and 34 patients received weekly cis-
platin (40 mg/m2) as a radio sensitizer.
Following CRT, all patients were evaluated for surgery. Seven patients 
were found to be inoperable. Indications for inoperability were progressive 
disease in 2, insufficient tumor response in 3, poor general conditions in 1 
patient, and the refusal of surgery by 1 patient. These patients underwent 
consolidation brachytherapy. Thirty-four patients were assigned for surgery.
Surgery
Radical hysterectomy was performed 4 to 6 weeks after completion of CRT. 
Surgery consisted of type 2 Wertheim hysterectomy including resection 
of the uterosacral and vesicouterine ligaments, unroofing, and mobilizing 
of the ureter to the lateral side, permitting a transection of the parametria 
and paracervical tissue at the level of the ureteral tunnel. At least 15 to 20 
mm of the vagina from the cervix or tumor was resected. To reduce poten-
tial risk of ureteric fistulas, the ureters were not stripped. Consequently, 
the surrounding mesoureter with its underlying blood vessels remained 
unharmed.
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Eighteen patients underwent a (limited) pelvic lymphadenectomy. A mean number 
of 11 lymph nodes (range, 1–31) were resected.
The mean operative time was 116 minutes (range, 60–235 minutes). The mean 
estimated blood loss was 500 mL. Six patients required a postoperative blood 
transfusion. No ureter, bladder, or bowel injuries occurred.
The operative mortality rate was nil. The median duration of hospital stay was 8 
days (range, 5–137 days). No urinary/digestive fistulae or stenoses were noted. 
One patient developed a paralytic ileus, and another had an intestinal subobstruc-
tion. Both patients were successfully treated conservatively.
Three patients were diagnosed with a postoperative urinary infection. Eleven 
patients (32%) had problems with urinary retention when the bladder catheter 
was removed. At the time of hospital discharge, 5 of these patients required 
self-catheterization. All urinary retention problems resolved spontaneously within 
3 months after the procedure.
In 4 cases, clinically significant lymphoceles occurred. One of these patients 
stayed hospitalized for more than 4 months because of a massive lymphocele 
producing more than 1 L lymph fluid a day. Her treatment was complicated by 
a surinfection with methicillin-resistant Staphylococcus aureus. In TABLE 2, the 
results concerning perioperative and postoperative complications are summarized.
Tumor resection margins were free of disease in all 34 cases. Complete patholog-
ical response was observed in 14 patients (41, 2%). Residual tumor was present 
in pelvic lymph nodes in 16% of patients with positive lymph nodes on pretreat-
ment 18FDG PET-CT. In TABLE 3, the results on pathology are summarized.
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 Radical Hysterectomy
No. patients   34
With (elective) lymphadenectomy, n
Complete lymphadenectomy 
Elective or directed lymphadenectomy
  18 
    8 
  10
No lymphadenectomy, n   16
Mean (range) operative time, min 116 (60-235)
Intraoperative complications, n (%)
Hemorrhage (> 1000 mL) 
Urinary injury 
Bowel injury 
Other injury
    3 (8.8) 
    3 (8.8) 
    0 (0) 
    0 (0) 
    0 (0)
Mean (range) intraoperative blood loss, mL 500 mL (100-2000)
Postoperative mortality, n (%)     0 (0)
Postoperative reintervention, n (%)     0 (0)
Wound infection, n (%)     0 (0)
Pelvic infections, n (%)     0 (0)
Hemorrhage, n (%)     0 (0)
Postoperative blood transfusion, n (%)     6 (17.6)
Urinary infection, n (%)     3 (8.8)
Urinary retention, n (%)
Grade 1 
Grade 2
  11 (32.3) 
    6 (17.4%) 
    5 (14.5)
Urinary fistulae, n (%)     0 (0)
Urinary stenosis, n (%)     0 (0)
Digestive fistulae, n (%)     0 (0)
Ileus, n (%)     1 (2.9)
Bowel subobstruction, n (%)     1 (2.9)
Pulmonary embolism, n (%)     0 (0)
Symptomatic lymph cysts, n (%)
Grade 1 
Grade 2
    4 (11.7) 
    2 (5.8) 
    2 (5.8)
Other complications, n (%)     0 (0)
Mean (range) hospital stay, d     8 (5-137)
TABLE 2: perioperative and postoperative complications.
 
Abdominal Hysterectomy
Type of resection, n (%)
R0 
R1 of 2
 
  34 (100) 
    0 (0)
Pathological response to IMAT (C) RT (n=34), % (n)
Complete response 
Tumor rest <5 mm 
Tumor rest >5 and <10 mm 
Tumor rest >10 mm
 
  41.2 (14/34) 
  20.6 (7/34) 
  17.6 (6/34) 
  20.6 (7/34)
Pathological response of PET + LN to (C)RT 18 patients had (elective)  lymphadenectomy (18/34 = 52.9%)
yN03 15 (15/18 = 83.3% or 15/34=44.1%)
yN1 3 (3/18=16.6% or 3/34=8.8%)
TABLE 3: pathological results of operated patients.
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Follow-up and Assessment of Disease Control in the Surgery Group
In the group of operated patients, 1 patient had a local relapse (vaginal top) within 
6 months after surgery. There was 1 pelvic lymph node relapse. Two patients 
developed distant metastasis (1 in the liver and a lung, respectively) within the 
first year after hysterectomy. Both patients died within 18 months after surgery. 
In the Wertheim group, OS and disease-free survival (DFS) at 3 years were 81% 
and 91%. In all patients intended to treat, OS and DFS at 3 years were 63% and 
74% (TABLE 4).
DISCUSSION
Completion surgery after CRT is controversial as there is until now no random-
ized study showing a survival benefit. In addition, there are concerns regarding 
morbidity of surgery following CRT. Keys et al7 included 256 eligible patients with 
bulky exophytic or “barrel”-shaped IB tumors. These patients were randomized to 
either EBRT and intracavitary irradiation (n = 124) or EBRT followed by extrafas-
cial hysterectomy (n = 132). They reported complete pathological response rates 
 
Intention to Treat (n=41) Surgery Only (n=34)
OS
1 y 
2 y 
3 y 
Estim 5 y
 
90% 
73% 
63% 
63%
 
97% 
87% 
81% 
81%
DFS
1 y 
2 y 
3 y 
Estim 5 y
 
80% 
74% 
74% 
74%
 
91% 
91% 
91% 
91%
Disease-specific survival
1 y 
2 y 
3 y 
Estim 5 y
 
90% 
77% 
67% 
67%
 
97% 
93% 
87% 
87%
Local relapse-free survival
Local relapses 
1 y 
2 y 
3 y 
Estim 5 y
 
8 
76% 
76% 
76% 
76%
 
1 
97% 
97% 
97% 
97%
Follow-up, mo
Median 
Min 
Max
 
24 
7.67 
63.67
 
28 
12 
63.67
TABLE 4: follow up results.
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in 48% of patients. There was macroscopically persistent disease in 12% of the 
patients. Interestingly, patients with bulky IB2 disease who underwent adjuvant 
hysterectomy had an improved 5-year DFS of 62% compared with 53% in the 
group without complementary surgery. This improvement was mostly related to a 
decrease in the rate of local recurrences after hysterectomy (15% vs 27%). Unfor-
tunately, this improvement in DFS did not translate into an improved OS. Reasons 
for lacking survival benefit could be a relatively limited number of patients in each 
arm and the absence of effective adjuvant therapy for patients at risk of having 
systemic metastases. Another reason might be the lack of number of patients with 
locally advanced disease who are at risk of having persisting disease following 
CRT, as Green et al2 showed in their meta-analysis. Nevertheless, a subgroup 
analysis showed a significant survival benefit in favor of complementary hysterec-
tomy in patients with tumors measuring 4 to 6 cm. Houvenaeghel et al8 confirmed 
that adjuvant surgery could improve the outcome of patients with bulky residual 
tumor (≥2 cm) after CRT for LACC. In addition, they stated that even if survival 
was not improved, complementary surgery resulted in a better quality of life 
before metastatic spread, as local recurrence is a source of chronic pelvic pain.
Because only a randomized trial could adequately determine whether completion 
surgery would be therapeutically beneficial, the GYNECO 02 study was started 
in 2002.9 This multicenter phase III trial comparing hysterectomy with no hyster-
ectomy in patients with a clinical and radiological complete response after CRT 
for stage IB2 or II cervical cancer was closed after 3 years because of insufficient 
accrual. A major reason for this poor accrual was the preference of the partici-
pating physicians toward hysterectomy. Nevertheless, 61 patients were included 
and were investigated. Although the study was underpowered, some interesting 
results were observed. Nearly one third of the patients undergoing adjuvant hys-
terectomy with a complete clinical and radiological response still had residual 
disease on histopathology.
In literature, the rate of residual cancer after chemoradiotherapy on surgical speci-
men ranges from 32% and 59%, depending on the study or FIGO stage.5,7,11 As for 
our study, we report a residual disease of 59% (38% with residual disease <1 cm, 
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21% with residual ≥1 cm). An explanation for this high percentage of residual 
disease when compared with literature could be 3-fold: (1) surgery was performed 
after CRT without brachytherapy; (2) surgery consisted of Wertheim type 2 com-
pared with simple hysterectomy in all referred articles; (3) surgery was performed 
4 to 6 weeks after ending IMAT, whereas the effect of radiotherapy tends to 
last longer.
There is a lot of concern regarding morbidity in case of complementary hysterec-
tomy after CRT. This concern might be legitimated in cases where conventional 
radiation technology was applied. However, as shown previously, the introduc-
tion of IMAT significantly lowered grades 3 and 4 radiotherapy-related toxicity.5 In 
addition, IMAT also reduces the dose to what we call “supportive” tissues, making 
complementary surgery easier, certainly from a technical point of view, and mak-
ing it possible to perform a radical hysterectomy (type II Wertheim) to remove also 
the parametria and a vaginal manchet of approximately 2 cm. Although out of the 
operated patients in our study 27% were more than FIGO stage III* we achieved 
an R0 resection in all cases (100%).
In 2 patients, the residual tumor was mainly found in the parametrium and would 
have been missed or ended in a transection of the tumor when surgery would 
have been limited to simple hysterectomy. The 3 year OS and DFS in this group 
were, respectively, 81% and 91%.
Generally, stage IV is considerate inoperable. We think a selected subgroup of 
patients with a satisfying response to CRT could benefit from complementary sur-
gery. Our study included 2 patients with stage IV disease. The first had pathologi-
cally proven bladder invasion that regressed completely following CRT. Therefore, 
bladder-conserving surgery could be performed. Tumor-free resection margins 
were obtained. 
* Correction on advise of a member of the examination committee: ”FIGO stage III” should be “FIGO 
stage IIB”
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The second patient had PET-positive pelvic and para-aortic nodal spread. She 
obtained complete remission on PET-CT scan following CRT with therapeutic 
pelvic and para-aortic field. Therefore, she was considerate to be operable, and 
Wertheim type II with selective pelvic and para-aortic lymph node dissection were 
performed. No residual disease was found on pathological examination of pelvic 
and para-aortic lymph nodes. Only residual disease (6 mm) was encountered in 
the cervix. Obtained resection margins were free of tumor.
Performing completion surgery after CRT also remains the only method to cor-
rectly assess the extent of residual disease, which is, after all, the most important 
prognostic factor. This allows determining a personalized postsurgical updated 
risk profile, which could be largely different than at initial diagnosis.12
Although lymph node status is one of the principal prognostic factors of cervi-
cal cancer, it is not included in the current FIGO classification. After CRT treat-
ment, about 16% of patients are left with positive pelvic lymph nodes. This rate 
increases if the primary tumor is radioresistant.13,14 Initially, a pelvic lymphadenec-
tomy was performed in all our patients. However, because the number of positive 
lymph nodes was limited, and all positive lymph nodes were located at the initial 
positive PET-CT location, this policy was changed, and only the PET-CT–posi-
tive lymph nodes were removed. It is nevertheless important to remember that 
complications after pelvic lymphadenectomy following IMAT were not negligible: 
2 patients had persisting lymphoceles that needed prolonged hospitalization for 
repeated evacuation, and even in 1 patient a lymphatic microanastomosis was 
performed. In contradiction, after adapting the lymph node dissection protocol as 
described previously, no significant lymphoceles developed.
The arguments against adjuvant surgery are mainly related to the fear of surgical 
morbidity after CRT. The risk of surgical complications depends on the radicality 
of the surgical procedure. In the series of Keys et al,7,15 grades 3 and 4 morbidity 
was not altered by hysterectomy after radiotherapy if compared with nonoperated 
patients (10% in each group). These findings were confirmed by Ferrandina et al,16 
who observed a low percentage of intraoperative and postoperative complications. 
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In those series, simple hysterectomy was the type of surgery, whereas in our 
series a more extensive surgery (Wertheim type II ± lymphadenectomy) was per-
formed. Nevertheless, we found low operative and postoperative complications. 
When compared with the surgical morbidity data after hysterectomy for low-stage 
cervical cancer, presented in the overview article by Trimbos et al,17 the rates of 
surgical morbidity from our series were comparable: (1) postoperative mortality 
less than 1% versus 0%; (2) urinary tract infection: 42% versus 9%; (3) deep 
venous thrombosis: 3% versus 3%; and (4) fistula: 2% versus 0%. These favor-
able operative and postoperative findings differ from previous reports described 
by Resbeut et al18 and Jurado and Martínez-Monge11 possibly because of (1) 
the use of additional brachytherapy or intraoperative radiotherapy in their series 
and (2) the use of IMAT radiotherapy in our series, which allows more precise 
targeting of tumor and relative sparing of surrounding normal organs and tissues.
In addition, surgical complication rates should be weighed against adverse 
effects such as the higher frequency of chronic proctitis and vaginal stenosis with 
decreased sexual function that are observed when patients receive brachyther-
apy as a standard treatment.
 
CONCLUSIONS
We believe that the implementation of advanced radiotherapy techniques with 
a higher radiation dose on the target volume and less damage to the organs at 
risk creates opportunities to safely perform radical hysterectomy and a tailored 
lymphadenectomy. Complication rates of type II hysterectomy after IMAT + C are 
acceptable and comparable to complication rates of radical surgery for low-stage 
cervical cancer.
REMARK: The text is identical to the one published in the journal
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ABSTRACT
Objective
In this study we evaluated the value of cervical biopsies in predicting residual 
disease after initial (chemo) radiotherapy in the treatment of local advanced cer-
vical cancer (LACC).
Materials and Methods
Since August 2012 all consecutive patients with LACC, treated with a multimodal-
ity treatment protocol consisting of Intensity Modulated Arc Therapy and concom-
itant chemotherapy (IMAT-C) followed by Wertheim type 2 surgery, were included 
in the study. All patients underwent cervical biopsies at the time of surgery using 
the ©Spirotome Cervicore device. At least 4 biopsies per case were performed. 
Pathology results of the biopsies were compared with the results of the resection 
specimen obtained through surgery.
Results
Ten consecutive patients were included. The mean age of patients was 66 years. 
The majority presented with squamous cell carcinoma (70%), 30% of patients had 
an adenocarcinoma. At the time of diagnosis all but two patients were classified 
FIGO stage IIB, the two other patients were staged FIGO IIIB. In 4 patients, no 
viable tumor cells were found. Six patients had residual disease. Only in 3 out of 
all cases with residual disease (n=6) the biopsies were able to predict persisting 
disease. The sensitivity, specificity, negative and positive predictive value for the 
biopsy result in predicting the presence of residual tumor was 50%, 100%, 57% 
and 100% respectively.
Conclusions
Only in half of the patients with residual disease (sensitivity of 50%) cervical 
biopsies could prove malignancy. This indicates it is not reliable for evaluating 
treatment response. We therefore can not recommend routine application of this 
technique for selecting LACC patients for hysterectomy following (chemo) radio-
therapy.
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INTRODUCTION
With an estimated 528,000 new cases in 2012 worldwide, cervical cancer is the 
fourth most common malignancy to affect women. It accounts for 7.5% of all 
female cancer deaths (266,000 in 2012). Around 85% occurs in the less devel-
oped regions.¹ Management of patients with cervical cancer depends on the 
stage of disease at time of diagnosis. The staging of cervical cancer is based on 
the International Federation of Gynecology and Obstetrics (FIGO) staging system. 
Since the meta-analysis of Green et al², based on 8 randomized trials, the combi-
nation of external beam radiotherapy (EBRT) and cisplatin-based chemotherapy 
(EBRT-C) followed by intracavitary brachytherapy is considered to be the standard 
treatment for bulky IB and locally advanced cervical cancer (LACC) up to stage 
IVA. The acute and long- term toxicity of this treatment is however not neglect-
able3. A valuable alternative is performing a (Wertheim or extrafascial) hyster-
ectomy after C-EBRT. Our group has demonstrated the feasibility, safety and 
therapeutic power of such an approach, with very promising (early) results.4,5 
These results are confirmed in a recent paper by Sun at al.6 Technical evolutions 
in radiotherapy planning and delivery such as intensity-modulated radiotherapy 
(IMRT) and intensity-modulated arc therapy (IMAT) are being implemented 
successfully thanks to the use of multimodality imaging for treatment planning and 
image-guided radiotherapy for treatment delivery.7 As a result, the combination of 
delivering a higher dose to the target volume and meanwhile lowering the dose 
to the small intestine, bone marrow, bladder and rectum has become perfectly 
feasible7. The ultimate goal is in an increase in the therapeutic ratio, which is the 
result of a higher disease control and a lower toxicity rate.
In cases with complete clinical response and negative cervical biopsies after the 
C-EBRT an additional treatment (such as brachytherapy) might not be necessary 
and consequently, treatment toxicity could be further reduced. However, it is not clear 
whether the combination of a complete clinical response and negative cervical biop-
sies corresponds with a complete pathological response (so-called ypT0 disease). 
This study emphasizes on the value of cervical biopsies in predicting residual disease 
after initial IMAT-C. To the best of our knowledge, this has never been studied before. 
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MATERIALS AND METHODS
Since 2007, patients referred to our centre with biopsy proven LACC are treated 
with a multimodality treatment protocol consisting of IMAT-C (IMAT and 40 mg/
m2 cisplatin weekly) followed by Wertheim type 2 surgery3, 4. According to the 
study protocol (n° B67020072880) surgery was performed 4 to 6 weeks after fin-
ishing IMAT-C. Prior to surgery all patients were evaluated on treatment response 
by clinical examination, magnetic resonance imaging (MRI) and 18FDG PET-CT. 
Since August 2012 all patients underwent cervical biopsies at the time of surgery 
using the ©Spirotome Cervicore device (®Medinvents, Hasselt, Belgium). At least 
4 biopsies per case were performed. Biopsies were guided by clinical findings. 
In case of lack of macroscopic residual disease biopsies were randomly taken in 
the four cervical quadrants (3-6-9-12 o’clock).  Pathology results of the biopsies 
were compared with the results of the resection specimen obtained through sur-
gery. Of the Wertheim hysterectomy specimens, the cervix was sectioned into 
3-mm slices and entirely embedded in paraffin blocks. Hematoxylin and eosin 
slides were meticulously evaluated for residual tumor. Lack of residual tumor was 
confirmed by immunohistochemistry broad-spectrum cytokeratin stains. Residual 
tumor on the surgical specimen was staged according to TNM classification (5th 
edition). To indicate that this staging was after neoadjuvant CRT, all pTN stages 
were preceded by “y”.
RESULTS
By December 2013 ten consecutive patients were included. Patients’ characteris-
tics are summarized in TABLE 1.The mean age of patients was 66 years. The vast 
majority presented with squamous cell carcinoma (70%), while 30% presented 
with adenocarcinoma. At the time of diagnosis all but two patients were classified 
FIGO stage IIB. The two other patients were staged FIGO IIIB. 
Pathological examination was performed on all Wertheim hysterectomy speci-
mens. Surgical margins were negative in all cases (R0 resection). In 4 patients, 
no viable tumor cells were found (ypT0). Six patients had residual disease. 
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One patient was pathologically staged as ypT1a2 (6mm residual disease (RD)), 
3 as ypT1B1 (10, 11 and 30 mm RD respectively) and 2 as ypT2a1 (9 an 30 mm 
RD respectively). Details on pathological results are shown in TABLE 2. Only in 
3 out of 6 cases with RD the biopsies were able to predict persisting disease, 
resulting in a sensitivity of 50%. All cases where there was a discrepancy between 
core biopsy and Wertheim specimen were squamous cell carcinoma. The sensi-
tivity, specificity, negative and positive predictive value for the biopsy result in 
predicting the presence of viable tumor at the hysterectomy specimen was 50%, 
100%, 57% and 100% respectively. The accuracy was 70%. 
 
 Patient
Tumor  
type
Residual  
disease (RD)
Max. size residual 
disease (cm)
Pathological staging  
post IMAT (ypT) Biopsy
1 SCC no RD 0 ypT0 no RD
2 SCC RD 0.6 ypT1a2 no RD
3 AC RD 3 ypt1b1 RD
4 SCC RD 0.9 ypT2a1 no RD
5 SCC RD 1.1 ypT1b1 no RD
6 AC RD 3 ypT2a1 RD
7 AC no RD 0 ypT0 no RD
8 SCC RD 1 ypt1b1 RD
9 SCC no RD 0 ypT0 no RD
10 SCC no RD 0 ypT0 no RD
TABLE 2: Pathological results.  
SCC: squamous cell carcinoma - AC: adeno carcinoma - RD: residual disease
 Patients characteristics n=10
Age, mean (range), y    66 (47 - 80)
Tumor type, % (n) 
     Sqamous cell carcinoma 
     Adenocarcinoma
 
   70 (7) 
   30 (3)
FIGO Stage (consensus), % (n) 
     FIGO IIB 
     FIGO IIIB
 
 80 (8) 
 20 (2)
Pathological complete Response % (n) 
     complete response 
     residual disease
                              40 (4) 
                              60 (6)
Response by stage (n) 
     complete response FIGO IIB 
     complete response FIGO IIIB
 
                       2 (2 out of 8) 
                       2 (2 out of 2)
TABLE 1: Patients characteristics.
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DISCUSSION
The standard recommendation for treatment of FIGO stages IB2 and IIB-IVA cer-
vical cancer is C-EBRT followed by brachytherapy2, 8.  Completion surgery after 
(C)RT is controversial as there is until now no randomized study showing a sur-
vival benefit so far. In addition, there are concerns regarding morbidity of surgery 
following (C)RT, certainly if conventional EBRT techniques are used. 9
However the implementation of IMAT allowed delivering a higher radiation dose 
on the target volume while lowering the dose to the organs at risk creates, hereby 
creating the opportunity to safely perform a radical hysterectomy and a tailored 
lymphadenectomy with surgical complication rates comparable to these of rad-
ical surgery for low-stage cervical cancer5. In this study we evaluated the value 
of cervical biopsies in predicting therapy response after IMAT-C.
We used the ®Spirotome Cervicore system consisting of a cutting helix com-
bined with a cutting cannula. This device was developed specifically for cervical 
disease that needs a representative and high quality diagnostic biopsy from both 
the mucosa and submucosal structures.  A high quality sample with a penetra-
tion depth of 20 mm can be obtained, which is larger and penetrates deeper than 
when classical biopsy instruments are used. This deep penetration is useful in 
evaluating treatment response, since (chemo) radiation therapy induces diffuse 
ulceration and erosion of the tumor with, often, residual disease beyond the sur-
face of the cervix.
In literature, the rate of residual cancer after CRT on surgical specimen ranges 
from 32% to 59%, depending on the study or FIGO stage5,10,11,12. In a previ-
ous report based on a larger subset of patients treated with the same treatment 
protocol, we documented residual disease in 59% of patients. In this smaller sub-
set of patients we found residual disease in 60%, showing this smaller group to 
be representative for the study population. Although this number is at the upper 
edge of the reported literature data, it can be easily explained. At first, we omitted 
brachytherapy from the treatment protocol and delivered a simultaneous boost 
to the tumor using IMAT alone. Secondly surgery consisted of Wertheim type 2 
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hysterectomy while in most referred articles, the authors used a simple hysterec-
tomy. Thirdly surgery was performed 4 to 6 weeks after ending IMAT, whereas the 
effect of radiotherapy tends to last longer. Finally, but probably very important, is 
the fact that the median initial diameter of the tumor in our study population was 
substantially larger than in comparable trials5.  
Only in half of the patients with residual disease (sensitivity of 50%) cervical 
biopsies showed malignancy. Although we performed multiple cervical biopsies 
(4 each patient) using an advanced biopsy device (resulting in larger and deeper 
biopsies) these results should be considered disappointing.  Not surprisingly, as 
shown in TABLE 2, the smaller the residual tumor, the higher risk of obtaining a 
false negative biopsy. These data are based on a small set of patients and further 
data on this topic are being collected.
CONCLUSIONS
Based on a small subset of patients it seems that cervical biopsies after EBRT 
has only a sensitivity of 50% to predict residual disease. The residual disease 
load was inversely related to the predictive value of the biopsy. These preliminary 
disappointing results of cervical biopsies post (chemo) radiotherapy for LACC 
strongly suggest that completion surgery should not be omitted in our treatment 
protocol.
REMARK: the text is identical to the one submitted to the journal
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Chapter 6:  
Discussion
6.1 Is there need for a FIGO face-lift?
Cervical cancer is a global health crisis that is still responsible for more than 
266.000 female deaths annually worldwide1. More than 80% of cervical cancer 
cases occur in low resource countries. The “epidemic” of cervical cancer in the 
sub Sahara countries is a reflection of the dramatic gap in health care between 
industrialized and underdeveloped countries in all its aspects from prevention, 
through screening and ending with management.2,3,4 The limited health care facil-
ities in low resource countries result in retarded diagnosis with as consequence 
often an advanced stage of disease, associated with a poor overall prognosis. 
Recent introduction in industrialized countries of advanced imaging tech-
niques have proven their value in assessing the extent of local disease (mainly 
MRI)5,6 and distant spread including lymph node invasion7 (CT and PET (CT)). 
Lymph node invasion is not included in the conventional FIGO staging system, 
but requires early detection and treatment and is an important prognostic factor. 
The most reliable diagnostic and therapeutic option is a systematic lymph node 
dissection. However this approach has a risk for (post)operative complications 
and therefore non invasive methods for detection of lymph node metastasis are 
required. In a large prospective study on the value of FDG-PET/CT for detecting 
pelvic lymph node invasion in 120 cervical cancer patients with > Ib, Loft et al.8 
found a sensitivity of 75%, specificity of 96%, positive predictive value of 75% 
and a negative predictive value of 96%. These values were 100%, 99%, 94% and 
100% for detection of para-aortic lymph node invasion and 100%,94%, 63% and 
100 % for the detection of distant metastasis.
MRI and PET/CT are not accessible in low resource countries and the inclu-
sion of its results in FIGO staging would imbalance the staging system resulting in 
incomparability of the obtained results. The success of FIGO staging is therefore 
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mainly based on the fact that it can be used worldwide. Nevertheless from being 
an ideal staging system to be used in comparing treatment results and prognosis, 
it is expected to be reliable and reproducible. Although used for almost a century 
no data on the accuracy of FIGO staging are available. In a prospective study 
(see chapter 4)9 we examined the interobserver agreement of the examination 
under anaesthesia (EUA) on which FIGO staging mainly is based, in order to 
investigate its reliability and reproducibility. Our data demonstrated only a mod-
erate inter observer agreement (IOA) on the FIGO stage among experienced 
investigators. These results should be considered disappointing and could indi-
cate possible limitations for sharing and comparing results based on this staging 
system. At present time the therapeutic impact of the moderate agreement on 
FIGO stage seems limited since we found an almost perfect IOA between expe-
rienced examiners on their treatment proposal. This can be explained by the 
fact that currently only few therapeutic options are considered as standard treat-
ment10,11 : 1) surgery as primary option for early stage non-bulky disease and 2) 
chemo radiation for more advanced disease. 
Our data demonstrated a significant better agreement concerning FIGO stage 
between experienced investigators than between an experienced and an inex-
perienced investigator. This resulted consequently in a lower level of agreement 
concerning the choice of therapy between experienced and inexperienced inves-
tigators. This implies that clinical gynecological examination is a skill that can be 
improved by training. Additionally it stipulates that patients should be staged by at 
least one experienced clinician in order to obtain the best possible clinical staging. 
A close look to the disagreement patterns on FIGO stage showed that in case of 
discrepancy the inexperienced investigator tended to underestimate the disease 
stage (by rating the FIGO stage to be lower than the rating of the experienced 
examiner) and consequently recommended surgery in patients that were con-
sidered inoperable by the experienced examiner. This could implicate a potential 
risk of suboptimal surgeries, with positive surgical resection margins and conse-
quently need for adjuvant radiotherapy (RT). Overall this would result in a sub-
optimal treatment with an increased risk of morbidity12 and higher medical costs.
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In order to evaluate possible confounding factors of the clinical cervical can-
cer FIGO staging we investigated the impact on the IOA of some patient or tumor 
related characteristics. Multivariate analysis could not demonstrate a significant 
impact on the IOA of any of the investigated characteristics. It is important to 
stress that all exams were performed under general anaesthesia. This could 
explain why for example Body Mass Index (BMI), in these optimal conditions, had 
no major impact on the clinical staging of cervical cancer. 
For gynecological cancers there has been tremendous movement over the 
last decade toward centralization of care into specialized centres. This comes 
from the recognition that multidisciplinary care, including access to opinions 
from gynecologic, medical, and radiation oncologists, can improve patient out-
comes13,14. In addition to this input, it is important to have access to subspecialty 
pathology, diagnostic radiology, oncology nursing, and other disciplines as neces-
sary. We think that the demonstrated impact of the experience of the practitioner 
on the reliability of cervical cancer staging is an important additional argument 
for further centralization of care in cervical cancer. In addition centralization in 
high volume hospitals would facilitate an optimal training in cancer staging and 
management. In low resource countries, where optimal conditions and additional 
imaging is often not available, the experience of the investigator is probably even 
more important. In these countries, in addition to an organized screening15 and 
an adjusted vaccination program2,3,4, the specialized training of the practitioners 
is a top priority that could result in a significant improvement on the overall prog-
nosis of cervical cancer patients.
While for the coming decennia in low resource countries FIGO staging based on 
clinical examination will stay the corner stone in the management of cervical can-
cer, its significance in industrialized countries will be challenged by the evolution 
in imaging technology. Therefore the latest revision of the FIGO staging in 200916 
remarked that advanced imaging techniques are useful (and even advisable 
when available) in therapeutic decision-making, but should not be used to alter 
the FIGO stage. This remark is a reflection of the reality in developed countries 
where the use of advanced imaging is more standard than exception in treatment 
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planning17,18. Recently advanced imaging techniques have been included by the 
National Comprehensive Cancer Network among the procedures for pretreatment 
work-up of cervical cancer.19 This evolution in imaging techniques together with 
innovations in radiation therapy created new therapeutic approaches that permit 
a more tumor delineated treatment, associated with less morbidity, better qual-
ity of life (QOL) and hopeful survival results. This is most needed in advanced 
disease (bulky disease and LACC) where survival rates still stay disappointing. 
Therefore the ethical issue arises whether one should stick to a clinical based 
staging system of cervical cancer in order to be able to compare results of out-
come of treatment and thereby ignoring the advantages of new diagnostic tools 
is more important than allowing improvement in cervical cancer care through a 
tailored approach based on these new diagnostic tools. Exclusion of advanced 
techniques could slow down research for new treatment modalities, predictive 
markers and prognostic factors. 
In conclusion we think that in the present global health care situation there is 
no possibility to introduce a general applicable new ”face-lifted” FIGO staging sys-
tem. Nevertheless, in industrialized countries the availability of advanced imag-
ing techniques creates opportunities for a makeover in treatment planning and in 
individualization of management that will be at least associated with better QOL. 
However the application of these advanced techniques in the management of 
cervical cancer can hamper comparison of different treatments outcomes unless 
included within a standardized framework.    
 
6.2  The (re)introduction of completion surgery  
 in the treatment of LACC in an era  
 of advanced radiotherapy
Since the publication by Green et al.20 in 2001 of a meta-analysis demonstrat-
ing the additional effect of chemotherapy when added to RT in the treatment of 
LACC, external beam radiotherapy (EBRT) with cisplatin based concomitant 
chemotherapy followed by brachytherapy (BT) is considered standard treatment 
for bulky IB and locally advanced cervical cancer (LACC) up to stage IVA21,22,23,24. 
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A Cochrane review in 200525 confirmed these findings: chemo radiation (CRT), 
when compared to RT alone, improves overall survival (OS) and progression 
free survival (PFS) with absolute benefits of 10% and 13% respectively. It also 
showed a significant benefit for local recurrence and a benefit of distant recur-
rence of borderline significance. These findings have suggested the hypothesis 
that concomitant chemotherapy may afford radio-sensitization and systemic cyto-
toxic effects26. Nevertheless, the meta-analysis of Green20 showed a rather limited 
survival benefit for LACC in the group with FIGO stages III–IVA. In order to obtain 
better results some groups adopted the idea of performing completion surgery 
after CRT27,28,29,30. The rationale for this idea is to obtain a better local control that 
might translate into a better OS. 
 
6.2.1 Favouring arguments for completion surgery
The rationale for completion surgery is double. Firstly it allows the removal of 
potential radiation therapy–resistant tumor foci29,31 and secondly it permits the 
assessment of the pathological response to the initial treatment. The presence 
and size of residual disease (RD) is a strong prognostic factor for future recur-
rence31,32,33,34. Depending on the study or FIGO stage, the rate of RD after CRT 
on the surgical specimen ranges from 45% to 70% 27,29,31,35,36. The chance of RD 
after primary CRT is dependent on initial stage of disease.37 We reported a RD of 
59% (publication 3)38 (38% with RD <1 cm, 21% with RD ≥1 cm) and 60% (pub-
lication 4)39. The incidence of RD in our series is rather high because of 3 main 
reasons. A) We omitted BT from the treatment protocol and delivered a simul-
taneous boost to the tumor using IMAT alone. B) We performed Wertheim type 
2 extended hysterectomy that included parametrial and vaginal wall resections 
while simple hysterectomy was performed in most previous publications27,29,31. The 
parametrium or the vaginal-cuff was the only site of RD in 5.8 % of our patients. 
Sun et al.40 reported an overall RD of 12% in parametria and 4.2% in the top of 
the vagina were reported. With a simple hysterectomy this RD would not have 
been detected. C) Surgery was performed 4 to 6 weeks after RT, whereas the 
effect of RT tends to last longer. The timing of surgery has an impact on RD rates 
(see TABLE 6.2). D) Last but not least the average initial diameter of the tumor in 
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our study population was substantially larger (5.3 cm) than in comparable trials. 
(See TABLE 6.2)
Since patients with RD are at risk for an early recurrence there is an urge for 
an additional treatment in order to improve their prognosis. 
 
6.2.2  Concerns regarding the morbidity  
  of completion surgery 
Ever since the option of completion surgery was proposed there has been a lot 
of concern regarding its morbidity32. Intra- and postoperative complication rates 
of completion surgery depend, as in primary surgery, mainly on the extent of the 
procedure. More complications are seen when surgery consists of Piver41 III or IV 
and in case of extended (pelvic and/or para-aortic) lymph node dissections42,43,44,45. 
In a recent paper by Ferrandina44 et al. 25.7 % of patients experienced any grade 
postoperative complications, 16.6 % had ≥ grade 2 complications and grade 
3-4 complications occurred in 5.8 % of patients. In this study 86.5 % of patients 
underwent type III-IV radical hysterectomy. Adopting class II radical hysterec-
tomy we showed low operative and postoperative complications even though sur-
gery was performed after CRT. Our complication rates are comparable to these 
reported after primary surgery for low-stage disease46,47. 
 
Pahisa47 Trimbos46 Tummers38
Mortality 0% < 1% 0%
Venous thromboembolism 8.7% 3% 3%
Bowel injury 0% NA 0%
Bladder injury 8.7% NA 0%
Ureter injury 4.3% NA 0%
Urinairy tract infection NA 42% 9%
Postoperative transfusion 26.1% 32% 17.6%
Fistula NA 2.1% 0%
TABLE 6.1: peri-operive complications. Pahisa and Trimbos: primary Wertheim surgery, Tummers: 
Wertheim post chemo radiotherapy. (NA= data not available)
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The low morbidity rates in our series can also be explained by the fact that: all 
of our patients were primarily treated by Intensity Modulated Arc Therapy (IMAT) 
which permits more precise targeting of the tumor and relative sparing of sur-
rounding/ normal organs and tissues. We are convinced that the concern about 
serious operative morbidity might be more legitimated in cases where conven-
tional radiation technology is applied. It is known that the introduction of advanced 
RT techniques such as intensity-modulated radiotherapy (IMRT) and IMAT is 
associated with a better therapeutic ratio and a significant decrease in grade 3 
and 4 RT-related toxicity30,48. In addition it also reduces the radiation dose to what 
we call uterine suspensory ligaments. This creates new opportunities for comple-
tion surgery. It makes complementary surgery easier, certainly from a technical 
point of view, and makes it possible to perform a more radical hysterectomy to 
remove also the parametria and the upper 2 cm of the vagina. Another explana-
tion for our morbidity rates might be the fact that all patients have been operated 
on by experienced gynecologic oncologists (first and second authors). 
The use of additional brachytherapy or intraoperative radiotherapy in previous 
reports could have a negative impact on the complication rates. In our series 
we avoided brachytherapy by performing surgery. Omitting brachytherapy is 
associated with lesser frequency of chronic proctitis and vaginal stenosis (with 
decreased sexual function). These adverse effects are not neglectable and can 
have a significant impact on the QOL certainly when taking into account most 
women with cervical cancer are diagnosed before the age of 50. 
After CRT treatment, about 16% of patients are left with positive pelvic lymph 
nodes. This rate increases if the primary tumor is radio-resistant 49,50. Initially, a 
pelvic lymphadenectomy was performed in all our patients during completion sur-
gery. However, because the number of positive lymph nodes was limited, and all 
positive lymph nodes were located at the initial positive 18FDG PET-CT location, 
our policy was changed, and only the PET-CT–positive lymph nodes (or lymph 
node areas) were removed. It is nevertheless important to remember that com-
plications after pelvic lymphadenectomy following CRT are not negligible. In our 
series 2 patients had persisting lymphocoeles that needed prolonged hospitalization 
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for repeated evacuation, and even in 1 patient a lymphatic micro-anastomosis 
was performed. In contradiction, after modification of the lymph node dissection 
protocol no significant lymphoceles developed.
6.2.3 Impact of completion surgery on survival rates
Until now no data are available from a large prospective randomized controlled 
trial proving a benefit in OS of patients with bulky IB and locally advanced cervi-
cal cancer (LACC) up to stage IVA treated with (C)RT followed by (radical) hys-
terectomy in comparison with patients managed by standard treatment ((C)RT + 
brachytherapy). 
Few papers were published regarding completion surgery after CRT. Comparison 
of the results of different institutions hampered by heterogeneity of different con-
founding factors including disease stage, dose of RT, modalities or chemotherapy, 
achievement of brachytherapy and type of surgery. Analysis of the outcome of 
completion surgery is therefore infeasible. In TABLE 2 we tried to highlight some 
specific issues.
# patients FIGO 
stage
mean initial 
size (cm) Piver
time window 
for surgery 
(weeks)
residual 
disease 
%
survival (%)
Keys et al. 199920 132 IB2 NA I 2-6 weeks 52.0% 5-year DFS = 62%
Houvenaeghel  
al. 200528 35
IB2-
IVA NA I-IV 4-10 weeks 54.2%
10-year DFS = 66.4%
10-year OS = 57.7%
Classe et al. 
200630 175
IB2-
IVA NA I-IV 4-6 weeks 61.1%
5-year OSC=89%
5-year OSP=54%
Huguet et  
al. 200832 92
IB-IIA-
IIB 4.9 cm II 3-14 weeks 45.5%
2-year DFS = 80.4%
2-year OS= 93.8%
5-year DFS = 72.2%
5-year OS= 78%
Ferrandina et al. 
201050 174
IB2-
IVA NA III 4-14 weeks 56.3%
5-year DFS = 75.5%
5-year OS= 77.4%
Tummers et al. 
201337 31
IB2-
IVA 5.3 cm II 4-6 weeks 58.8%
3-year DFS= 91%
3-year OS = 81%
Wang et al. 
201435 119 IIB 4.5 cm ns 2-3 weeks 68.9%
3-year DFS= 91%
3-year OS= 94.9%
TABLE 2 : Illustration of the diversity of reported data on OS and DFS in completion surgery for bulky 
and locally advanced cervical cancer. (DFS= disease free survival, OS= overall surviv-
al, OSC= overall survival in case of complete response, OSP= overall survival in case of 
partial response)
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Keys et al21 included 256 eligible patients with bulky exophytic or “barrel”-shaped 
IB tumors. These patients were randomized to either RT plus brachytherapy (n = 
124) or RT followed by extrafascial hysterectomy (n = 132). They reported com-
plete pathological response rates in 48% of patients. There was macroscopically 
RD in 12% of the patients. Interestingly, patients with bulky IB2 disease who 
underwent adjuvant hysterectomy had an improved 5-year DFS of 62% compared 
with 53% in the group without complementary surgery (p=0.09). The difference 
reached significance (p=0.04) when comparisons were adjusted for tumor size, 
performance status and age. This improvement was mainly related to reduced 
local recurrence rate after hysterectomy (15% versus 27%). Unfortunately, this 
improvement in DFS was not translated into significantly improved OS. Reasons 
for lacking survival benefit could be a relatively limited number of patients in each 
arm and the absence of effective adjuvant therapy for patients at risk of having 
systemic metastases (those with RD after CRT). Another reason might be the 
lack of number of patients with LACC who are at risk of having RD following CRT 
as shown by meta-analysis of Green et al20. Nevertheless, a subgroup analysis 
showed a significant survival benefit in favor of complementary hysterectomy 
in patients with tumors measuring 4 to 6 cm. In addition, the authors stated that 
even if survival was not improved, complementary surgery resulted in a better QOL 
before metastatic spread, as local recurrence is a source of chronic pelvic pain. 
In a recently published prospective trial Wang et al.36 compared two groups of 
patients with FIGO stage IIB cervical carcinoma treated either with RT followed 
by radical surgery (n = 119) or with RT followed by brachytherapy (n = 121). This 
report is however not a randomized trial since patient’s preference decided on 
treatment modality. They showed a 3-year OS benefit of 10.3 % (94.9% versus 
84.6%, p=0.011) and a 3-year PFS benefit of 9.2% (91.0 versus 81.8%, p=0.049) 
in favour of patients that received completion surgery. The results of this trial are 
very promising. 
Because only a randomized controlled trial could adequately determine whether 
completion surgery would be therapeutically beneficial, the GYNECO 02 study35 
was started in 2002. This multicentre phase III trial comparing hysterectomy with 
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no hysterectomy in patients with a clinical and radiological complete response 
after CRT for stage IB2 or II cervical cancer was stopped after 3 years because 
of insufficient accrual. Nevertheless, 61 patients were included and were inves-
tigated (arm A with surgery: 30 patients, arm B without surgery: 31 patients). 
Although the study was underpowered, results seem to suggest that completion 
surgery had no impact in these patients. A major reason for the poor accrual was 
the preference of the participating physicians toward hysterectomy and patients 
insisting on having the “initial site” of the tumor removed. Possible positive psy-
chological effect of the procedure is seldom reported in the literature. This study 
is one of the few that looked more carefully to this particular aspect and observed 
that patients submitted to the adjuvant procedure are highly satisfied. A number 
of women referred to subjective sense of relief, enhanced feeling of cancer cure, 
and improved self-esteem after extirpation of the affected organ. Further research 
on the QOL after completion surgery is required.
The promising results from the first two trials and the fact that the only random-
ized controlled trial (RCT) was closed early because patients and practitioners 
favored completion surgery and therefore did not want to be randomized, urges 
for a new international multicentre RCT on this topic. 
 
6.2.4 How to select patients for completion surgery
In order to reduce the overall toxicity of the treatment in patients with LACC it 
would be opportune if we could select patients with RD after initial RT treatment 
that would benefit adjuvant treatment. Consequently this would mean that we 
would be able to avoid additional brachytherapy and/or surgery (or other treat-
ment modalities) in patients without RD. This could minimalize the treatment tox-
icity without deteriorating the prognosis. 
In a pilot study we used the ®Spirotome Cervicore system to evaluate the 
value of cervical biopsies in predicting therapy response after CRT (using IMAT). 
This device was developed specifically for cervical disease that needs a represen-
tative and high quality diagnostic biopsy from both the mucosa and submucosal 
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structures. A high quality sample with a penetration depth of 20 mm can be 
obtained, which is larger and penetrates deeper than when classical biopsy 
instruments are used. This deep penetration is useful in evaluating treatment 
response, since (chemo) radiation therapy induces diffuse ulceration and ero-
sion of the tumor with, often, RD beyond the surface of the cervix. Only in half of 
the patients with RD (sensitivity of 50%) cervical biopsies were contributory and 
showed malignancy. Although we performed multiple cervical biopsies (4 each 
patient) using this advanced biopsy device, false negative results were observed 
in 50% of patients. Based on these disappointing results we can conclude that 
cervical biopsy is not valuable in predicting pathological response in patients 
with LACC after an initial IMAT+C treatment because of its low sensitivity. As 
demonstrated in Morice et al.35, patients with a clinical and radiological (MRI and 
PET-CT) complete response to initial CRT + brachytherapy still showed in more 
than 30% of cases residual disease on pathological examination of hysterectomy 
specimen after surgery, demonstrating the poor reliability of preoperative clinical 
and radiological evaluation in predicting RD after CRT. In a study by Fanfani et 
al.52 2013 cone biopsies were used to predict the treatment response in FIGO 
IB2-IIB cervical cancer patients to neo-adjuvant CRT. Results showed cone biop-
sies accurately identified patients with complete and microscopic partial patho-
logical response. The negative predictive value (NPV) of cone biopsy was 100%. 
In their series the NPV of MRI and PET-CT was 79% and 79%. A close look to 
the presented data showed that: 1) In 25% of patients the intended cone biopsy 
was omitted because of stenosis of the top of the vagina or because of the com-
plete cervical tissue retraction. 2) The cone biopsy was performed at the time of 
surgery, while when to use it in order to predict response to initial treatment it 
should be performed prior to surgery. After a cone biopsy it is advisable to wait 
several (on average 6) weeks before performing (radical) hysterectomy in order 
to avoid additional complications. This would delay surgery beyond the ideal time 
window (4-6 weeks after CRT) concerning radiotherapy related fibrosis. Overall 
we think these data on cone biopsy are encouraging but a larger study to verify 
the safety, real life feasibility (cone biopsy prior to surgery) and oncological effi-
cacy are needed before it should be considered a valid option for the pathological 
response evaluation of LACC patients undergoing neo-adjuvant CRT. 
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6.3 Future perspectives on …
(FIGO) staging
• The experience of the investigator is an important confounding factor in 
the reliability of FIGO staging of cervical cancer. In low resource coun-
tries where there is no/limited access to (advanced) imaging techniques, 
this experience is probably even more crucial, since treatment planning 
relies (completely) on clinical FIGO staging. Centralization of care in high 
volume hospitals would optimize staging and treatment conditions and 
would facilitate better training opportunities. It is obvious that this change 
towards centralization in management of cervical cancer care needs a 
global approach driven by an institution such as the World Health Orga-
nization. Our research on this topic could help to put this item on their 
agenda. Ideally it should be part of a master plan covering also sex-edu-
cation, screening, adapted HPV vaccination programs and HIV preven-
tion and treatment. 
• In a sequel to our study on the reliability of clinical FIGO staging, we want 
to add in all patients the information of MRI and PET-CT to the data in 
order to investigate on which indications their input in staging is required/
favourable. 
• The application of advanced imaging techniques in the management of 
cervical cancer in industrialized countries can hamper comparison of dif-
ferent treatments outcomes. Therefore there is a need for a standardized 
framework in treatment planning. 
Treatment of LACC
• A prospective randomized trial comparing 1) complementary surgery 
following CRT with 2) standard treatment (EBCRT + BT) in patients with 
bulky and locally advanced cervical cancer is required. The design of this 
study should take consideration to all different aspects such as survival 
benefit and QOL (including sexuality).
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• A prediction model could help us in the selection of patients without RD 
after initial CRT treatment that can be saved unnecessary additional 
treatment such as complementary surgery or brachytherapy. We plan to 
investigate if the combination of information obtained by clinical exam-
ination, tumor markers, cone/core biopsies, MRI and PET-CT could lead 
to an accurate prediction model of RD. 
• Patients with persisting disease after CRT are at high risk of disease 
recurrence and distant metastases. An additional effective consolidation 
therapy is urgently required in this subcategory as no efficient chemo-
therapy is available. Further investigations within field of targeted therapy 
or therapeutic vaccination are needed.
 
6.4 Conclusions
FIGO staging
• We describe a moderate interobserver agreement on clinical staging of 
patients with cervical cancer. These results should be considered disap-
pointing and could indicate possible limitations for sharing and comparing 
results based on this staging system. 
• In order to obtain an optimal clinical staging of cervical cancer it should 
be performed by an experienced investigator and under optimal condi-
tions including general anesthesia.
• Staging by an inexperienced investigator is associated with a significant 
higher risk of under staging. This might result in unnecessary surgeries, 
more need for adjuvant therapy and can result in increased morbidity and 
costs. 
• The skill of clinical staging of cervical cancer can be improved by training 
within a centralized cancer care. 
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Treatment of LACC
• Type II Wertheim surgery after initial CRT with IMAT for bulky or locally 
advanced cervical cancer is feasible and is associated with low morbidity. 
• Our data regarding completion surgery following primary CRT with IMAT 
for bulky/locally advanced cervical cancer are promising. These findings 
urge for a large international prospective randomized trial. 
• Cervical biopsy has low sensitivity in predicting pathological response in 
patients with LACC after an initial IMAT+C treatment.
100
References
1. Cervical Cancer Incidence, Mortality and prevalence worldwide in 2012: 
Summary. http://globocan.iarc.fr/factsheet.asp (Accessed on January 2014) 
2. van Bogaert Lj. Are the currently existing anti-human papillomavirus vaccines ap-
propriate for the developing world? Ann Med Health Sci Res. 2013 Jul;3(3):306-12.
3. Steben M, Jeronimo J, Wittet S, Lamontagne DS, Ogilvie G, Jensen C, Smith 
J, Franceschi S. Upgrading public health programs for human papillomavi-
rus prevention and control is possible in low- and middle-income countries. 
Vaccine. 2012 Nov 20;30 Suppl 5:F183-91
4. Agosti JM1, Goldie SJ. Introducing HPV vaccine in developing countries--key 
challenges and issues. N Engl J Med. 2007 May 10;356(19):1908-10 
5. Thomeer MG, Gerestein C, Spronk S, van Doorn HC, van der Ham E, Hun-
ink MG. Clinical examination versus magnetic resonance imaging in the pre-
treatment staging of cervical carcinoma: systematic review and meta-analysis. 
Eur Radiol. 2013 Jul;23(7):2005-18.
6. Sahdev A, Reznek RH. Magnetic resonance imaging of endometrial and 
cervical cancer. Ann N Y Acad Sci. 2008 Sep;1138:214-32. 1138:214Y23
7. Tropé C, Kristensen G, Onsrud M, Bosze P. Controversies in cervical cancer 
staging. CME J Gynaecol Oncol 2001;6:240-5
8. Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, Neder-
gaard L, Højgaard L, Engelholm SA. The diagnostic value of PET/CT scan-
ning in patients with cervical cancer: a prospective study. Gynecol Oncol. 
2007 Jul;106(1):29-34.
9. Tummers P, Gerestein K, Mens JW, Verstraelen H, van Doorn H. Interobserver 
variability of the International Federation of Gynecology and Obstetrics stag-
ing in cervical cancer. Int J Gynecol Cancer. 2013 Jun;23(5):890-4
10. NCCN guidelines cervical cancer. http://www.nccn.org/professionals_gls/pdf/
cervical.pdf
11.  ESGO guidelines cervical cancer http://www.esgo.org/Education/Documents/
Algorithms%20english%20version.pdf
12. Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams A sys-
tematic review of acute and late toxicity of concomitant chemoradiation for 
cervical cancer. Radiother Oncol. 2003 Sep;68(3):217-26. Review. 
101
13. Ghaemmaghami F, Hassanzadeh M, Karimi-Zarchi M, Modari-Gilani M, Be-
htash A, Mousavi N. Centralization of ovarian cancer surgery: do patients 
benefit? Eur J Gynaecol Oncol. 2010;31(4):429-33.
14. Reade C, Elit L. Trends in gynecologic cancer care in North America. Obstet 
Gynecol Clin North Am. 2012 Jun;39(2):107-29.
15. Bradford L1, Goodman A. Cervical cancer screening and prevention in low-re-
source settings. Clin Obstet Gynecol. 2013 Mar;56(1):76-87.
16. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the 
cervix. Int J Gynaecol Obstet. 2009 May;105(2):107-8.
17. Liyanage SH1, Roberts CA, Rockall AG. MRI and PET scans for primary 
staging and detection of cervical cancer recurrence. Womens Health (Lond 
Engl). 2010 Mar;6(2):251-67
18. Tomita N, Toita T, Kodaira T, Shinoda A, Uno T, Numasaki H, Teshima T, Mit-
sumori M. Changing trend in the patterns of pretreatment diagnostic as-
sessment for patients with cervical cancer in Japan. Gynecol Oncol. 2011 
Dec;123(3):577-80.
19. National Comprehensive Cancer Network: www.nccn.org/professionals /
physician_gls
20. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Wil-
liams CJ (2001). Survival and recurrence after concomitant chemotherapy 
and radiotherapy for cancer of the uterine cervix: a systematic review and 
meta-analysis. The Lancet. 2001 Sep 8;358(9284):781-6. 
21. Keys HM1, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 
3rd, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy 
compared with radiation and adjuvant hysterectomy for bulky stage IB cervi-
cal carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61.
22. Morris M1, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, 
Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy 
compared with pelvic and para-aortic radiation for high-risk cervical cancer. 
N Engl J Med. 1999 Apr 15;340(15):1137-43.
23. Rose PG1, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pear-
son DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy 
for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53.
102
24. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, 
Grigsby P, Gordon W Jr, Alberts DS. Concurrent chemotherapy and pelvic 
radiation therapy compared with pelvic radiation therapy alone as adjuvant 
therapy after radical surgery in high-risk early-stage cancer of the cervix.J 
Clin Oncol. 2000 Apr;18(8):1606-13.
25. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, Williams C, 
Collingwood M. Concomitant chemotherapy and radiation therapy for cancer 
of the uterine cervix. Cochrane Database Syst Rev. 2005 Jul 20;(3)
26. Modarress M1, Maghami FQ, Golnavaz M, Behtash N, Mousavi A, Khalili 
GR. Comparative study of chemoradiation and neoadjuvant chemotherapy 
effects before radical hysterectomy in stage IB-IIB bulky cervical cancer and 
with tumor diameter greater than 4 cm. Int J Gynecol Cancer. 2005 May-
Jun;15(3):483-8.
27. Keys HM, Bundy BN, Stehman FB, et al.Gynecologic Oncology Group. 
Radiation therapy with and without extrafascial hysterectomy for bulky stage 
IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. 
Gynecol Oncol. 2003; 89: 343–353.
28. Azria E, Morice P, Haie-Meder C, Thoury A, Pautier P, Lhomme C, Duvillard P, 
Castaigne D. Results of hysterectomy in patients with bulky residual dis-
ease at the end of chemoradiotherapy for stage IB2/II cervical carcinoma. 
Ann Surg Oncol. 2005 Apr;12(4):332-7
29. Houvenaeghel G, Lelievre L, Gonzague-Casabianca L, et al. Long-term sur-
vival after concomitant chemoradiotherapy prior to surgery in advanced cer-
vical carcinoma. Gynecol Oncol. 2006; 100: 338–343.
30. Vandecasteele K, De Neve W, De Gersem W, et al. Intensity-modulated 
arc therapy with simultaneous integrated boost in the treatment of primary 
irresectable cervical cancer. Treatment planning, quality control, and clinical 
implementation. Strahlenther Onkol. 2009; 185: 799–807.
31. Classe JM, Rauch P, Rodier JF, et al.; Groupe des Chirurgiens de Centre 
de Lutte Contre le Cancer. Surgery after concurrent chemoradiotherapy and 
brachytherapy for the treatment of advanced cervical cancer: morbidity and out-
come: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens 
de Centre de Lutte Contre le Cancer). Gynecol Oncol. 2006; 102: 523–529.
103
32. Touboul C, Uzan C, Mauguen A, et al. Prognostic factors and morbidities after 
completion surgery in patients undergoing initial chemoradiation therapy for 
locally advanced cervical cancer. Oncologist. 2010; 15: 405–415.
33. Huguet F, Cojocariu OM, Levy P, Lefranc JP, Darai E, Jannet D, Ansquer Y, 
Lhuillier PE, Benifla JL, Seince N, Touboul E. Preoperative concurrent radia-
tion therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of 
the uterine cervix with proximal parametrial invasion. Int J Radiat Oncol Biol 
Phys. 2008 Dec 1;72(5):1508-15
34. Ferrandina G, Legge F, Fagotti A, et al. Preoperative concomitant chemora-
diotherapy in locally advanced cervical cancer: safety, outcome, and prog-
nostic measures. Gynecol Oncol. 2007; 107:S127YS132
35. Morice P, Rouanet P, Rey A, et al. Results of the GYNECO 02 Study, an FN-
CLCC phase III trial comparing hysterectomy with no hysterectomy in patients 
with a (clinical and radiological) complete response after chemoradiation 
therapy for stage IB2 or II cervical cancer. Oncologist. 2012; 17: 64–71.
36. Wang N, Li WW, Li JP, Liu JY, Zhou YC, Zhang Y, Hu J, Huang YH, Chen Y, 
Wei LC, Shi M. Comparison of concurrent chemoradiotherapy followed by rad-
ical surgery and high-dose-rate intracavitary brachytherapy: a retrospective 
study of 240 patients with FIGO stage IIB cervical carcinoma. Onco Targets 
Ther. 2014 Jan 6;7:91-100
37. Motton S, Houvenaeghel G, Delannes M, Querleu D, Soulé-Tholy M, Hoff J, 
Lèguevaque P. Results of surgery after concurrent chemoradiotherapy in 
advanced cervical cancer: comparison of extended hysterectomy and extra-
fascial hysterectomy. Int J Gynecol Cancer. 2010 Feb;20(2):268-75
38. Tummers P, Makar A, Vandecasteele K, De Meerleer G, Denys H, De Visschere P, 
Delrue L, Villeirs G, Lambein K, Van den Broecke R. Completion surgery after 
intensity-modulated arc therapy in the treatment of locally advanced cervi-
cal cancer: feasibility, surgical outcome, and oncologic results. Int J Gynecol 
Cancer. 2013 Jun;23(5):877-83.
39. Tummers P, Makar A, Vandecasteele K, De Meerleer G, Denys H, De Visschere P, 
Delrue L, Lambert, B, Lambein K, Van den Broecke R. Value of cervical 1 bi-
opsy in predicting tumor response of primary locally advanced cervical cancer 
after treatment with intensity-modulated arc therapy: a prospective pathology- 
matched pilot study. Submitted to European J. Cancer.
104
40. Sun L, Sheng X, Jiang J, Li X, Liu N, Liu Y, Zhang T, Li D, Zhang X, Wei P. 
Surgical morbidity and oncologic results after concurrent chemoradiation 
therapy for advanced cervical cancer. Int J Gynaecol Obstet. 2014 Jan 24
41. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for 
women with cervical cancer. Obstet Gynecol 1974;44:265-72 
42. Jurado M, Martínez-Monge R, García-Foncillas J, et al. Pilot study of concur-
rent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical 
surgery +/– intraoperative electron beam radiotherapy in locally advanced 
cervical cancer. Gynecol Oncol. 1999; 74: 30–37.
43. Resbeut M, Cowen D, Viens P, et al. Concomitant chemoradiation prior to 
surgery in the treatment of advanced cervical carcinoma. Gynecol Oncol. 
1994; 54: 68–75.
44. Ferrandina G1, Ercoli A, Fagotti A, Fanfani F, Gallotta V, Margariti AP, Salerno 
MG, Chiantera V, Legge F, Macchia G, Morganti AG, Valentini V, Scambia G. 
Completion Surgery After Concomitant Chemoradiation in Locally Advanced 
Cervical Cancer: A Comprehensive Analysis of Pattern of Postoperative Com-
plications. Ann Surg Oncol. 2014 
45. Landoni F, Maneo A, Cormio G, Perego P, Milani R, Caruso O, Mangioni C.
Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: 
a prospective randomized study. Gynecol Oncol. 2001 Jan;80(1):3-12
46. Trimbos JB1, Franchi M, Zanaboni F, Velden Jv, Vergote I. ‘State of the art’ of 
radical hysterectomy; current practice in European oncology centres. Eur J 
Cancer. 2004 Feb;40(3):375-8.
47. Pahisa, Jaume; Martínez-Román, Sergio; Torné, Aureli et al. Comparative 
Study of Laparoscopically Assisted Radical Vaginal Hysterectomy and Open 
Wertheim-Meigs in Patients With Early-Stage Cervical Cancer: Eleven Years 
of Experience. International Journal of Gynecological Cancer. 20(1):173-178, 
January 2010.
48. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation ther-
apy (IMRT) reduces small bowel, rectum, and bladder doses in patients with 
cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol 
Biol Phys. 2001; 51: 261–266.
49. Dargent D, Lamblin G, Romestaing P, et al. Effect of radiotherapy on pelvic 
105
lymph node metastasis in cervical cancer stages IB2-IVA: a retrospective 
analysis of two comparative series. Int J Gynecol Cancer. 2005; 15: 468–474.
50. Houvenaeghel G, Lelievre L, Rigouard AL, et al. Residual pelvic lymph node 
involvement after concomitant chemoradiation for locally advanced cervical 
cancer. Gynecol Oncol. 2006; 102: 74–79.
51. Ferrandina G1, Margariti PA, Smaniotto D, Petrillo M, Salerno MG, Fagotti A, 
Macchia G, Morganti AG, Cellini N, Scambia G. Long-term analysis of clinical 
outcome and complications in locally advanced cervical cancer patients ad-
ministered concomitant chemoradiation followed by radical surgery. Gynecol 
Oncol. 2010 Dec;119(3):404-10.
52. Fanfani F, Fagotti A, Gagliardi ML, Ferrandina G, Monterossi G, Gallotta V, 
Zannoni GF, Scambia G. Pre-hysterectomy cone biopsy is able to predict 
response in locally advanced cervical cancer patients submitted to neo- 
adjuvant chemoradiation. Eur J Surg Oncol. 2013 Sep;39(9):1025-9.
106
Chapter 7:  
About the author
Personalia
 Surname  Tummers
 First Name   Philippe
 Place of Birth  Ghent, Belgium
 Date of Birth  January 4th, 1975
 Married to  Isabelle Stuyver
 Children   Victor Tummers
    Maurice Tummers
 Professional Address Vrouwenkliniek 
    Ghent University Hospital
    De Pintelaan 185
    9000 Ghent
    Belgium
    Tel +32 93320338
    Email: philippe.tummers@ugent.be
Education
1988-1993 :  Secondary school: Sint-Barbaracollege, Ghent
1993-2000 :  Medical doctor degree, July 2000,  
  Ghent University Hospital, Belgium
2001-2006 :  Legal Degree of Specialist in Obstetrics & Gynecology,  
  recognized by the department of Social Affairs,  
  Public Health and Environment of Belgium, 2006
2008-2010 :  Subspecialisation Gynecologic Oncology,  
  Erasmus MC Cancer Institute, Rotterdam,  
  The Netherlands, recognized by the NVOG, 2010
Professional
2000-2001 :  Pre-internship: Abdominal & Vascular Surgery,  
  (Sint-Vincentius Hospital, Deinze, Dr. L. Berrewouts)
2001-2006 : Internship Obstetrics & Gynecology: University Hospital Ghent, 
  Belgium (Prof. Dr. M. Dhont), William Harvey Hospital, Ashford,  
  Kent, UK (Mr. J. Seaton – Mr. G. Etokowo), MCRZ, Rotterdam, 
  The Netherlands (Dr.van Heusden)
107
2006-2007 :  OLV Aalst, Belgium, Resident in Obstetrics and Gynaecology
2007-2008 :  University Hospital Ghent, Belgium, Resident in Obstetrics  
  and Gynaecology
2008-2010 :  Erasmus MC, Rotterdam, The Netherlands:  
  Fellow Gynecologic Oncology
2010-onwards  :   University Hospital Ghent, Belgium,  
              Staff member Gynecology – Gynecological Oncology
Scientific Publications
Primary intestinal type adenocarcinoma of the female genital tract, arisen from a tubulo-vil-
lous adenoma: Case report. van Wessel S, Van Kerrebroeck H, Van Bogaert V, Tummers P, 
Van den Broecke R. Gynecol Oncol Case Rep. 2013 Jan 29;4:63-5. 
Leiomyomatosis peritonealis disseminata associated with ascites and endometriosis: 
a case report and review of the literature. De Vos T, Weyers S, Braems G, Villeirs G, 
Lambein K, Makar A, Tummers P, Van Den Broecke R. Acta Chir Belg. 2013 Sep-
Oct;113(5):357-63.
Completion surgery after intensity-modulated arc therapy in the treatment of locally ad-
vanced cervical cancer: feasibility, surgical outcome, and oncologic results. Tummers P, 
Makar A, Vandecasteele K, De Meerleer G, Denys H, De Visschere P, Delrue L, Villeirs G, 
Lambein K, den Broecke RV.
Int J Gynecol Cancer. 2013 Jun;23(5):877-83. 
Interobserver variability of the International Federation of Gynecology and Obstetrics 
staging in cervical cancer. Tummers P, Gerestein K, Mens JW, Verstraelen H, van Doorn H. 
Int J Gynecol Cancer. 2013 Jun;23(5):890-4.
Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irre-
sectable cervical cancer. Toxicity, tumour response and outcome. Vandecasteele K, Makar A, 
Van den Broecke R, Delrue L, Denys H, Lambein K, Lambert B, van Eijkeren M, Tummers P, 
De Meerleer G.
Strahlenther Onkol. 2012 Jul;188(7):576-81. 
Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: 
a prospective report on toxicity. Vandecasteele K, Tummers P, Makar A, van Eijkeren M, 
Delrue L, Denys H, Lambert B, Beerens AS, Van den Broecke R, Lambein K, Fonteyne V, 
De Meerleer G.
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):408-14. 
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and 
resectability of primary locally advanced cervical cancer after treatment with intensity-mod-
ulated arc therapy: a prospective pathology-matched study. Vandecasteele K, Delrue L, 
Lambert B, Makar A, Lambein K, Denys H, Tummers P, Van den Broecke R, Villeirs G, 
De Meerleer G. 
Int J Gynecol Cancer. 2012 May;22(4):630-7.
108
HPV-vaccinatie: rationale. P. Tummers, S. Weyers. Tijdschr. voor Geneeskunde, 2009, 65, 
120-122.
Number of women needed in a prospective trial to prove potential cardiovascular benefit 
of hormone replacement therapy. Depypere HT, Tummers P, De Bacquer D, De Backer G, 
Do M, Dhont M. Climacteric. 2007 Jun;10(3):238-43.
Het tubacarcinoom: een vaak vergeten pelviene tumor. P. Tummers, R. Van den Broecke, 
V. Schelfhout, R. Serreyn . Tijdschr. Voor Geneeskunde 2005, 61, 1226-1229.
Risk of spontaneous abortion in singleton and twin pregnancies after IVF/ICSI. P. Tummers, 
P. De Sutter, M. Dhont. Hum Reprod. 2003, Aug;18(8):1720-3.
Reiki en vruchtbaarheid: een leerzame casus van een heterotope drielingzwangerschap 
P Tummers, Petra De Sutter UGent and Marc Dhont UGent Gunaikea 2002; 7. p.246-251.
L. Crevits, M. Hanse, P. Tummers, G. Van Maele. Antisaccades and remembered saccades 
in mild traumatic brain injury. J. Neurol. 2000, 247,179-182.
L. Crevits, P. Tummers: Intactness of inhibitory saccade mechanism in minor traumatic 
head injury. Neuro-opthalmology 2000, 2, 339-342.
Conference contributions
Uteriene en ovariële tumoren. Wat verwacht de clinicus van de radioloog? Postgraduaat 
van de vlaamse radiologen, K. Vandecasteele, P. Tummers, 12/12/ 2013, Mondelinge 
presentatie.
ESGO highlights 2013, Gypon Symposium, P. Tummers, 03/12/13, Mondelinge presentatie
Work-up/Staging in pelviene oncologie :  hoe krijg ik de beste inlichting uit de beeldvorm-
ing? 1ste VVOG cursus pelviene oncologie. P. Devisschere, P. Tummers. 04/10/2013, Mon-
delinge presentatie
Anatomie en pathologie, colposcopiecursus VVOG, P. Tummers. 28/06/2013, Mondelinge 
presentatie.
Oncologische heelkunde bij hoog bejaarde patiënten, Naar een holistische aanpak van 
reproductieve, urogenitale en seksuele gezondheid, Symposium ter gelegenheid van de 
opening van het vernieuwde P3 – P4 complex . K. Decaestecker, P. Tummers,09/03/ 2013, 
Mondelinge presentatie.
Postoperatieve infecties: voorkomen en behandelen, cursus Gynaecologische infecties 
VVOG, P. Tummers, 08/03/2013, Mondelinge presentatie.
HPV vaccinatie: voor- en nadelen, economische aspecten en toekomst scenario. 
P. Tummers, Studiedag: HPV in het menselijk lichaam - van mond tot perineum, ZNA Mid-
delheim, 1/12/2012, Mondelinge presentatie.
109
Ambulante behandeling van cervixletsels, Ethiek en Economie VVOG, P. Tummers S. Wey-
ers. 28/04/2012, Mondelinge presentatie.
Ovarian Cancer: State of the Art, Role of surgery in recurrent, P. Tummers, GYPON sym-
posium,14/01/2012, Mondelinge presentatie.
Anatomie en pathologie, colposcopiecursus VVOG, P. Tummers, 17/06/2011, Mondelinge 
presentatie.
VVOG richtlijnen update 2011 diagnose en behandeling van vulvacarcinoma, P. Tummers, 
F. Ahankour, 21/10/2011, Mondelinge presentatie.
Gestational Trophoblastic Diseases, Postgraduaatcursus, P. Tummers, 10/12/2010, 
Mondelinge presentatie.
Doelgerichte en gepersonaliseerde medicatie: new hot spots bij borstkanker en pelviene 
gynaecologische tumoren, 2de VVOG Jaarcongres, P. Tummers. Concert Noble – Brussel, 
09/10/2010, Mondelinge presentatie.
Het tubo-ovarieel abces, De Doelencongres Rotterdam, P. Tummers, 06/03/2009, 
Mondelinge presentatie.
De rol van HPV bij het ontstaan van het cervixcarcinoom. GYPON meeting, P. Tummers, 
01/03/2008, Mondelinge presentatie.
M. Do, P. Tummers, G. Debacker, D. Debacquer, H. Depypere, M. Dhont: “Calculation of 
number of woman needed to treat with HRT to prove the effect on CVD”. Asse, Belgium, 
23/04/05, Mondelinge presentatie.
Intrapartum CTG. CTG cursus VVOG, Brussel, 17/09/05, Mondelinge presentatie
H. Depypere, P. Tummers, G. Debacker, D. Debacquer, M. Dhont. ”The ultimate HRT trial, 
an utopia?”. 11th World Congress on the Menopause, Buenos Aires, Argentina, 18/10/ 
2005, Oral presentation.
M. Do, P. Tummers, G. Debacker, D. Debacquer, H. Depypere, M. Dhont: “Calculation of 
number of woman needed to treat with HRT to prove the effect on CVD”. Asse, Belgium, 
23/04/05, Mondelinge presentatie.
Audit: cause of delay in discharge after day-case surgery. P. Tummers, T. Moriarthy, 
G. Etokowo. East Kent Obs&Gynae meeting, Canterbury, UK, 13/05/04, Oral presentation.
Audit: Cord-Blood Sampling. P. Tummers, G. Etokowo. East Kent Obs&Gynae meeting, 
Canterbury, UK, 02/07/04 . Oral Presentation.
Miscarriage risk in singleton versus twin pregnancies after IVF. P. Tummers, P. De Sutter, 
M. Dhont. ESHRE 2002, Viena, Austria, 03/07/02, Oral presentation.
Kans op miskraam bij 1- en 2-ling zwangerschappen ontstaan na IVF P. Tummers, 
P. De Sutter, M. Dhont. Gynaecongres VVOG/NVOG, Antwerpen, 31/05/02, Mondelinge 
presentatie.
110
Kans op miskraam na IVF. P.Tummers, P. De Sutter, M. Dhont. Vereniging voor Fertiliteit-
sonderzoek, Brussel, 17/05/02, Mondelinge presentatie.
--
Depression, anxiety and sexual dysfunction in women with breast cancer, S. Van Wessel, 
G. Braems, A. Makar, I. Jacobs, R. Van den Broecke, P. Tummers. ESGO Liverpool 
20/10/2013, Poster Presentation.
Neo-adjuvant chemoradiation for locally advanced cervical cancer: a promising report 
on outcome. K. Vandecasteele, P. Tummers, H. Denys,L. Delrue, R. Van den Broecke, 
K. Lambein, P. De Visschere, G. De Meerleer, ESGO Liverpool, 20/10/2013, Poster Presentation.
Whole abdominopelvic radiotherapy (WAPRT) using intensity modulated arc therapy 
(IMAT) as palliation for chemotherapy-resistent ovarian cancer. K. Vandecasteele, A. Makar, 
P. Tummers, H. Denys, R. Van den Broecke, L. Delrue, P. De Visschere, P. Ost, G. De Meerleer, 
IGCS Vancouver, 13/10/2012, Poster presentation.
Surgery after intensity modulated arc therapy in the treatment of locally advanced cer-
vical cancer: feasibility and surgical outcome. P. Tummers, A. Makar, K. Vandecasteele, 
G. De Meerleer, H. Denys, P. De Visschere, G. Villeirs, K. Lambein, R. Van den Broecke, 
IGCS Vancouver 14/10/2012, Poster presentation.
Surgery after after neo-adjuvant treatment with intensity modulated arc therapy + Cis-
platin for primary unresectable cervical cancer. P. Tummers, A. Makar, K. Vandecasteele, 
G. De Meerleer, H. Denys, P. De Visschere, G. Villeirs, K. Lambein, R. Van den Broecke, 
ESGO Milan, 12/09/2011, Poster presentation.
Inter-observer variability of FIGO staging in cervical cancer . P. Tummers, E. Birnie, 
J.W. Mens, C. Burger, H. van Doorn, IGCS Prague, 23/10/2010, Poster presentation.
Surgical morbidity of radical hysterectomy following intensity modulated arc therapy (IMAT) 
in the multimodality treatment of locally advanced cervical cancer. A. Makar, K. Vande-
casteele, G. Villeirs, H. Denys, R. Van den Broecke, V. Cocquyt, K. Lambein, V. Fonteyne, 
L. Delrue, P. Tummers, G. De Meerleer.ESGO Belgrade, 11/10/2009, Poster presentation.
The ultimate randomised HRT trial: an utopia? P. Tummers, G. Debacker, D. Debacquer, 
M. Dhont, H. Depypere. Menopauze vereniging. Brussel, 10/11/2005. Poster presentatie.
111
 Dankwoord
“Genieten van het leven zoveel je kan… dat is wijsheid”
                                                                                                  G. De Clercq-Colle 
Ik schreef dit dankwoord op een zomerse avond met zicht op de haven van Zee-
brugge…
Het beëindigen van een thesis is zo een van die momenten waarbij je stilstaat om een 
voorbije intense periode te overschouwen. Wat zijn de laatste jaren voorbij gevlogen… 
Terwijl het klinisch werk alleen maar toenam, werd de druk om deze thesis af te ron-
den almaar groter. Ik ben dan ook oprecht gelukkig en best wel fier dat het gelukt is. 
Zonder de hulp van velen zou dit niet mogelijk geweest zijn. Hen allen wil ik natuurlijk 
hartelijk bedanken. Enkelen wil ik hierbij in het bijzonder noemen. 
Een eerste woord van dank komt toe aan onze patiënten en hun familie. Het blijft alle 
dagen opnieuw een voorrecht om jullie vertrouwen te krijgen.  Jullie moed en levens-
lust zijn een bron van inspiratie en energie.
Een thesis zonder promotor is als een schip zonder kapitein. Beste Prof Van den 
Broecke, captain in charge, beste Rudy, jij was het die mij steunde in mijn plan om 
de weg van de gynaecologische oncologie in te slaan en jij overtuigde me ook om in 
het UZ Gent te komen werken. Van beide beslissingen heb ik nog steeds geen spijt 
gehad. Dank voor het vertrouwen. Tijdens de talrijke “belangrijke besprekingen “ op 
het einde van een drukke vrijdag nam je de tijd om me aan te moedigen in het the-
siswerk. Je overtuigingskracht gecombineerd met je wijnkennis hebben me enorm 
geholpen tijdens dit proces. Op die manier wist je er steeds de animo en goede sfeer 
in te houden. Jij bent een van die zeldzame mensen die meer vloeken wanneer ze 
goed gezind zijn: ik heb dan ook graag elke vloek in mijn richting als een waar com-
pliment aangenomen.
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breide kennis binnen ons vakgebied. Het is dan ook een voorrecht om wekelijks met 
je te kunnen samenwerken. Je was me aangekondigd als strenge leermeester maar ik 
heb je bovenal leren kennen als een oprechte en integere vriend. Hartelijk dank voor je 
aanhoudende en kritische ondersteuning bij het schrijven en verwerken van dit geheel. 
Als co-stuurvrouwen kon ik beroep doen op Prof. Hannelore Denys en Dr. Katrien 
Vandecasteele. Het was geen toeval dat ik jullie gekozen heb om mij te ondersteu-
nen bij dit lastig “corvee”: onze wegen kruisen dagelijks bij het behandelen van onze 
patiënten. De pelviene gynaecologische tumoren zijn dan ook ons gezamenlijk inte-
ressegebied.  Dank jullie voor de niet aflatende hulp bij dit werk. Katrien, jij was me al 
voorafgegaan met je doctoraat over de toepassing van IMAT radiotherapie  bij gynae-
cologische tumoren. Het was dan ook mooi om als een belangrijk deel van mijn thesis 
deze ingeslagen weg verder te bewandelen en de vernieuwde chirurgische mogelijk-
heden bij gevorderde cervixcarcinomen te bestuderen. 
Net als op een schip is een goede samenwerking cruciaal bij de behandeling van 
oncologische patiënten. Een multidisciplinaire benadering staat dan ook centraal in 
ons beleid bij gynaecologische tumoren. We zijn dan ook fier dat dit mogelijk is bin-
nen een optimale sfeer. Als jong en dynamisch team hebben we de laatste jaren het 
GYPON  (Gynaecologische Pelviene Oncologie Gent) op de kaart gezet. De aan-
houdende inzet van velen hierbij betrokken verklaart dan ook de gestage groei van 
onze activiteiten. In het bijzonder wil ik, naast de reeds genoemden, enkele betrok-
kenen bedanken: Prof. Gert De Meerleer, Dr. Pieter De Visschere, Dr. Louke Delrue, 
Prof. Geert Villeirs, Dr. Kathleen Lambein, Prof. Marleen Praet, Prof. Bieke Lambert, 
Dr. Karel Decaestecker en Dr. Dirk Van de Putte. Ook wil ik de collega’s van medi-
sche Genetica zeker niet vergeten. De bijkomende psychologische ondersteuning en 
begeleiding van onze patiënten wordt voorzien door onze psychologen onder leiding 
van mevr. Ingrid Jacobs. Tijdens het geheel van de behandeling wordt de patiënt bij-
gestaan door onze oncologie verpleegkundigen: in vaak moeilijke omstandigheden 
(te veel werk, te weinig middelen) zijn jullie een belangrijke steun en toeverlaat voor 
onze patiënten. 
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Een speciaal woord van dank gaat uit naar het verplegend personeel van onze afde-
ling 5K1: dankzij jullie dagelijkse inzet en toewijding krijgen onze patiënten de opti-
male postoperatieve zorgen die ze verdienen.  Jullie betrokkenheid is o zo belangrijk!
Een woord van dank ook voor al het personeel van de polikliniek en het  operatie-
kwartier voor jullie dagelijkse inzet en steun. Dank ook voor jullie begrip wanneer mijn 
spreekuur weer eens dreigde uit te lopen of wanneer ik weer net een beetje teveel 
operaties op mijn programma had gezet. Ik beloof jullie, van zodra er wat tijd over is, 
volg ik een cursus time-management!
Bedankt ook aan ons diensthoofd Prof. Weyers en alle collega’s voor de aangename 
en constructieve werksfeer aan boord van de vrouwenkliniek. In het bijzonder wil ik 
mijn 3 “buurmannen”  van 3B1 (Professoren Hans Verstraelen, Geert Braems en Wal-
ter Parewijck) vernoemen  die steeds klaar stonden met goede raad en opbeurende 
gesprekken wanneer ik overstag dreigde te gaan.
Voor mijn opleiding pelviene gynaecologische oncologie meerde ik 2 jaar aan in 
de grootste haven van Europa: Rotterdam. Al had ik al wat ervaring met werken in 
Nederland en al is mijn genetisch materiaal deels oranje gekleurd, toch was het even 
aanpassen aan het “Rotterdams Academisch Denkpatroon”. Professor Burger, beste 
Curt (ja, door mijn Vlaams gevoel voor hiërarchie duurde het bijna 2 jaar alvorens ik 
je zo durfde aan te spreken), het was een eer om onder uw leiding mijn fellowship te 
kunnen volgen. Ik blijf het jammer vinden dat U nu als diensthoofd gynaecologie-ver-
loskunde van het Erasmus Medisch Centrum opgeslorpt wordt door vergaderingen 
terwijl uw ware passie in de operatiezaal ligt. Het was steeds een plezier om de (ope-
ratie-) tafel met u te delen. Het onderzoek naar de betrouwbaarheid van de FIGO-sta-
diëring bij baarmoederhalskanker kon ik onder begeleiding van Dr. Lena van Doorn 
uitvoeren. Ook na mijn terugkeer naar Gent zorgde zij ervoor dat de studie kon wor-
den verdergezet. Kees Gerestein en Diederick de Jong, we begonnen als collega’s 
fellows, we zaten in hetzelfde schuitje , intussen bevaren we andere wateren. Het 
maakt niet uit of we elkaar privé of op congres terugzien, het blijft prettig om samen 
herinneringen op te roepen.
Prof. Sophie Vanbelle, wij hebben elkaar nog nooit ontmoet, ik kwam je op het spoor 
naar aanleiding van jouw toonaangevend artikel over “interobserver variability”. 
Desondanks was je bereid om me geheel belangeloos te begeleiden bij de statistiek. 
Fantastisch dat dit nog kan anno 2014!
Beste vrienden, zoals bij schippers van de lange omvaart lijkt het ook voor ons steeds 
veel te lang geleden dat we elkaar zagen. Toch blijven we elkaar volgen en aanmoe-
digen. Bedankt voor jullie onvoorwaardelijke steun en vriendschap. 
Dank ook aan mijn schoonfamilie voor de hulp bij de opvang van Victor & Maurice. 
Zonder jullie steun en flexibiliteit zou het vaak niet zo vlot lopen! 
Mama en papa, zonder jullie stond ik er nu niet. Dag na dag besef ik meer wat een 
voorrecht het is om samen met mijn broers in een warm nest te zijn opgegroeid. Door 
jullie hebben we alle kansen gekregen, nooit was iets teveel gevraagd. Nu is het aan 
jullie … “genieten van het leven, zoveel je kan…”
Broers, al zien we elkaar door de vele kilometers tussen ons wat minder vaak, al zijn 
we zo verschillend, we blijven elkaars grootste supporters. 
Liefste Victor & Maurice: een lach, een traan, een grap, een knuffel van jullie… en 
alles lijkt zo relatief. Ik hoop de komende periode wat minder vaak “Papa, mij niet 
opjagen!” te moeten horen en wat meer met jullie te kunnen ravotten. Plots lijkt huis-
werk maken en voorlezen een mooi vooruitzicht! Jullie zijn elkaars beste vriendjes 
en onze mooiste geschenken.
Allerliefste Isabelle, mijn mooiste woorden zijn voor jou. Zonder jou was mijn fel-
lowship en deze thesis nooit tot een goed einde gekomen. Je gaf me de ruimte om 
werk te combineren met ons gezin. Het is altijd heerlijk bij je thuiskomen.  Het is ont-
roerend te zien hoe onze jongens hun mama adoreren. Dank je voor je onvoorwaar-
delijke steun en liefde. Geen woorden kunnen beschrijven wat je voor me betekent. 
Ik zie je graag.
Philippe
